Drug O O
Interactions O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
-- O O
This O O
medicine O O
may O O
be O O
affected O O
by O O
the O O
drug O O
cholestyramine B-drug B-drug
and O O
should O O
not O O
be O O
taken O O
with O O
any O O
form O O
of O O
estrogen O B-group
therapy O O
. O O

Talk O O
to O O
your O O
pharmacist O O
for O O
more O O
information O O
. O O

Drugs O O
that O O
may O O
decrease O O
the O O
effects O O
of O O
this O O
medicine O O
include O O
: O O
Rifampin B-drug B-drug
barbiturates B-group B-group
phenytoin B-drug B-drug
( O O
Dilantin B-brand B-brand
) O O
carbamazepine B-drug B-drug
( O O
Tegretol B-brand B-brand
) O O
Estrogens B-group B-group
may O O
decrease O O
the O O
effects O O
of O O
benzodiazepines B-group B-group
( O O
lorezepam B-drug B-drug
oxezepam I-drug I-drug
temezepam I-drug I-drug
) O O
. O O

If O O
you O O
are O O
taking O O
these O O
medicines O O
together O O
or O O
you O O
have O O
further O O
questions O O
about O O
drug O O
interactions O O
talk O O
to O O
your O O
doctor O O
or O O
pharmacist O O
. O O

Consult O O
your O O
doctor O O
or O O
pharmacist O O
if O O
you O O
are O O
taking O O
any O O
of O O
the O O
following O O
: O O
seizure O O
medications O O
antibiotics B-group B-group
warfarin B-drug B-drug
medications O O
to O O
help O O
you O O
sleep O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
Infergen B-brand B-brand
. O O

Infergen B-brand B-brand
should O O
be O O
used O O
cautiously O O
in O O
patients O O
who O O
are O O
receiving O O
agents O O
that O O
are O O
known O O
to O O
cause O O
myelosuppression O O
or O O
with O O
agents O O
known O O
to O O
be O O
metabolized O O
via O O
the O O
cytochrome O O
P-450 O O
pathway.9 O O
Patients O O
taking O O
drugs O O
that O O
are O O
metabolized O O
by O O
this O O
pathway O O
should O O
be O O
monitored O O
closely O O
for O O
changes O O
in O O
the O O
therapeutic O O
and/or O O
toxic O O
levels O O
of O O
concomitant O O
drugs O O
. O O

Interactions O O
for O O
Dronabinol B-drug B-drug
: O O
In O O
studies O O
involving O O
patients O O
with O O
AIDS O O
and/or O O
cancer O O
, O O
MARINOL B-brand B-brand
( O O
Dronabinol B-drug B-drug
) O O
Capsules O O
has O O
been O O
co-administered O O
with O O
a O O
variety O O
of O O
medications O O
( O O
e.g. O O
, O O
cytotoxic O B-group
agents O I-group
, O O
anti-infective B-drug B-group
agents O I-group
, O O
sedatives B-group B-group
, O O
or O O
opioid B-group B-group
analgesics I-group I-group
) O O
without O O
resulting O O
in O O
any O O
clinically O O
significant O O
drug/drug O O
interactions O O
. O O

Although O O
no O O
drug/drug O O
interactions O O
were O O
discovered O O
during O O
the O O
clinical O O
trials O O
of O O
MARINOL B-brand B-brand
Capsules O O
, O O
cannabinoids B-group B-group
may O O
interact O O
with O O
other O O
medications O O
through O O
both O O
metabolic O O
and O O
pharmacodynamic O O
mechanisms O O
. O O

Dronabinol B-drug B-drug
is O O
highly O O
protein O O
bound O O
to O O
plasma O O
proteins O O
, O O
and O O
therefore O O
, O O
might O O
displace O O
other O O
protein-bound O O
drugs O O
. O O

Although O O
this O O
displacement O O
has O O
not O O
been O O
confirmed O O
in O O
vivo O O
, O O
practitioners O O
should O O
monitor O O
patients O O
for O O
a O O
change O O
in O O
dosage O O
requirements O O
when O O
administering O O
dronabinol B-drug B-drug
to O O
patients O O
receiving O O
other O O
highly O O
protein-bound O O
drugs O O
. O O

No O O
specific O O
interactions O O
are O O
known O O
at O O
this O O
time O O
. O O

Concomitant O O
Therapy O O
Special O O
care O O
should O O
be O O
exercised O O
in O O
treating O O
patients O O
who O O
are O O
receiving O O
concomitant O O
therapy O O
( O O
either O O
topically O O
or O O
systemically O O
) O O
with O O
known O O
photosensitizing O O
agents O O
such O O
as O O
anthralin B-drug B-drug
, O O
coal B-drug_n O
tar I-drug_n O
or O O
coal B-drug_n O
tar I-drug_n O
derivatives I-drug_n O
, O O
griseofulvin B-drug B-drug
, O O
phenothiazines B-group B-group
, O O
nalidixic B-drug B-drug
acid I-drug I-drug
, O O
halogenated B-group B-group
salicylanilides I-group I-group
( O O
bacteriostatic O O
soaps O O
) O O
, O O
sulfonamides B-drug B-group
, O O
tetracyclines B-group B-group
, O O
thiazides B-group B-group
, O O
and O O
certain O O
organic O O
staining O O
dyes O O
such O O
as O O
methylene B-drug_n B-drug
blue I-drug_n O
, O O
toluidine B-drug_n B-drug
blue I-drug_n O
, O O
rose O O
bengal O O
and O O
methyl O O
orange O O
. O O

There O O
have O O
been O O
no O O
studies O O
of O O
the O O
interaction O O
of O O
methyl B-drug B-drug
aminolevulinate I-drug I-drug
cream O O
with O O
any O O
other O O
drugs O O
, O O
including O O
local O O
anesthetics B-group B-group
. O O

It O O
is O O
possible O O
that O O
concomitant O O
use O O
of O O
other O O
known O O
photosensitizing O O
agents O O
might O O
increase O O
the O O
photosensitivity O O
reaction O O
of O O
actinic O O
keratoses O O
treated O O
with O O
methyl B-drug B-drug
aminolevulinate I-drug I-drug
cream O O
. O O

No O O
untoward O O
clinical O O
manifestations O O
have O O
been O O
observed O O
in O O
limited O O
experience O O
with O O
patients O O
in O O
whom O O
PRIMACOR B-brand B-brand
was O O
used O O
concurrently O O
with O O
the O O
following O O
drugs O O
: O O
digitalis B-group B-group
glycosides I-group I-group
; O O

lidocaine B-drug B-drug
, O O
quinidine B-drug B-drug
; O O

hydralazine B-drug B-drug
, O O
prazosin B-drug B-drug
; O O

isosorbide B-drug B-drug
dinitrate I-drug I-drug
, O O
nitroglycerin B-drug B-drug
; O O

chlorthalidone B-drug B-drug
, O O
furosemide B-drug B-drug
, O O
hydrochlorothiazide B-drug B-drug
, O O
spironolactone B-drug B-drug
; O O

captopril B-drug B-drug
; O O

heparin B-drug B-drug
, O O
warfarin B-drug B-drug
, O O
diazepam B-drug B-drug
, O O
insulin B-drug B-drug
; O O

and O O
potassium B-drug B-drug
supplements O O
. O O

Chemical O O
Interactions O O
There O O
is O O
an O O
immediate O O
chemical O O
interaction O O
which O O
is O O
evidenced O O
by O O
the O O
formation O O
of O O
a O O
precipitate O O
when O O
furosemide B-drug B-drug
is O O
injected O O
into O O
an O O
intravenous O O
line O O
of O O
an O O
infusion O O
of O O
PRIMACOR B-brand B-brand
. O O

Therefore O O
, O O
furosemide B-drug B-drug
should O O
not O O
be O O
administered O O
in O O
intravenous O O
lines O O
containing O O
PRIMACOR B-brand B-brand
. O O

Misoprostol B-drug B-drug
has O O
not O O
been O O
shown O O
to O O
interfere O O
with O O
the O O
beneficial O O
effects O O
of O O
aspirin B-brand B-brand
on O O
signs O O
and O O
symptoms O O
of O O
rheumatoid O O
arthritis O O
. O O

Misoprostol B-drug B-drug
does O O
not O O
exert O O
clinically O O
significant O O
effects O O
on O O
the O O
absorption O O
, O O
blood O O
levels O O
, O O
and O O
anti-platelet O O
effects O O
of O O
therapeutic O O
doses O O
of O O
aspirin B-brand B-brand
. O O

Misoprostol B-drug B-drug
has O O
no O O
clinically O O
significant O O
effect O O
on O O
the O O
kinetics O O
of O O
diclofenac B-drug B-drug
or O O
ibuprofen B-drug B-drug
. O O

Mitoxantrone B-drug B-drug
and O O
its O O
metabolites O O
are O O
excreted O O
in O O
bile O O
and O O
urine O O
, O O
but O O
it O O
is O O
not O O
known O O
whether O O
the O O
metabolic O O
or O O
excretory O O
pathways O O
are O O
saturable O O
, O O
may O O
be O O
inhibited O O
or O O
induced O O
, O O
or O O
if O O
mitoxantrone B-drug B-drug
and O O
its O O
metabolites O O
undergo O O
enterohepatic O O
circulation O O
. O O

To O O
date O O
, O O
post-marketing O O
experience O O
has O O
not O O
revealed O O
any O O
significant O O
drug O O
interactions O O
in O O
patients O O
who O O
have O O
received O O
NOVANTRONE B-brand B-brand
for O O
treatment O O
of O O
cancer O O
. O O

Information O O
on O O
drug O O
interactions O O
in O O
patients O O
with O O
multiple O O
sclerosis O O
is O O
limited O O
. O O

Following O O
concurrent O O
administration O O
of O O
NOVANTRONE B-brand B-brand
with O O
corticosteroids B-group B-group
, O O
no O O
evidence O O
of O O
drug O O
interactions O O
has O O
been O O
observed O O
. O O

May O O
interact O O
with O O
cimetidine B-drug B-drug
, O O
digoxin B-drug B-drug
, O O
medicines O O
to O O
control O O
heart O O
rhythm O O
, O O
sevelamer B-drug O
, O O
and O O
theophylline B-drug B-drug
. O O

Drug-drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
VIGAMOX B-brand B-brand
solution O O
. O O

In O O
vitro O O
studies O O
indicate O O
that O O
moxifloxacin B-drug B-drug
does O O
not O O
inhibit O O
CYP3A4 O O
, O O
CYP2D6 O O
, O O
CYP2C9 O O
, O O
CYP2C19 O O
, O O
or O O
CYP1A2 O O
indicating O O
that O O
moxifloxacin B-drug B-drug
is O O
unlikely O O
to O O
alter O O
the O O
pharmacokinetics O O
of O O
drugs O O
metabolized O O
by O O
these O O
cytochrome O O
P450 O O
isozymes O O
. O O

No O O
significant O O
drug O O
interactions O O
were O O
reported O O
in O O
studies O O
in O O
which O O
olmesartan B-drug B-drug
medoxomil I-drug O
was O O
co-administered O O
with O O
digoxin B-drug B-drug
or O O
warfarin B-drug B-drug
in O O
healthy O O
volunteers O O
. O O

The O O
bioavailability O O
of O O
olmesartan B-drug B-drug
was O O
not O O
significantly O O
altered O O
by O O
the O O
co-administration O O
of O O
antacids B-group B-group
[ O O
Al O B-drug
( O I-drug
OH O I-drug
) O I-drug
3/Mg O I-drug
( O I-drug
OH O I-drug
) O O
2 O O
] O O
. O O

Olmesartan B-drug B-drug
medoxomil I-drug O
is O O
not O O
metabolized O O
by O O
the O O
cytochrome O O
P450 O O
system O O
and O O
has O O
no O O
effects O O
on O O
P450 O O
enzymes O O
; O O

thus O O
, O O
interactions O O
with O O
drugs O O
that O O
inhibit O O
, O O
induce O O
or O O
are O O
metabolized O O
by O O
those O O
enzymes O O
are O O
not O O
expected O O
. O O

Potential O O
drug O O
interactions O O
between O O
OXISTAT B-brand B-brand
and O O
other O O
drugs O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

No O O
reported O O
significant O O
interactions O O

Severe O O
hypertension O O
has O O
been O O
reported O O
when O O
oxytocin B-drug B-drug
was O O
given O O
three O O
to O O
four O O
hours O O
following O O
prophylactic O O
administration O O
of O O
a O O
vasoconstrictor B-group B-group
in O O
conjunction O O
with O O
caudal O O
block O O
anesthesia O O
. O O

Cyclopropane O B-drug
anesthesia O O
may O O
modify O O
oxytocin B-drug B-drug
s O O
cardiovascular O O
effects O O
, O O
so O O
as O O
to O O
produce O O
unexpected O O
results O O
such O O
as O O
hypotension O O
. O O

Maternal O O
sinus O O
bradycardia O O
with O O
abnormal O O
atrioventricular O O
rhythms O O
has O O
also O O
been O O
noted O O
when O O
oxytocin B-drug B-drug
was O O
used O O
concomitantly O O
with O O
cyclopropane O B-drug
anesthesia O O
. O O

No O O
formal O O
drug-drug O O
interaction O O
studies O O
were O O
conducted O O
. O O

In O O
Trial O O
1 O O
, O O
the O O
proportions O O
of O O
patients O O
in O O
the O O
placebo O O
and O O
Synagis B-brand B-brand
groups O O
who O O
received O O
routine O B-group
childhood O I-group
vaccines B-group I-group
, O O
influenza B-group B-group
vaccine I-group I-group
, O O
bronchodilators B-group B-group
or O O
corticosteroids B-group B-group
were O O
similar O O
and O O
no O O
incremental O O
increase O O
in O O
adverse O O
reactions O O
was O O
observed O O
among O O
patients O O
receiving O O
these O O
agents O O
. O O

Palonosetron B-drug B-drug
is O O
eliminated O O
from O O
the O O
body O O
through O O
both O O
renal O O
excretion O O
and O O
metabolic O O
pathways O O
with O O
the O O
latter O O
mediated O O
via O O
multiple O O
CYP O O
enzymes O O
. O O

In O O
vitro O O
studies O O
indicated O O
that O O
palonosetron B-drug B-drug
is O O
not O O
an O O
inhibitor O O
of O O
CYP1A2 O O
, O O
CYP2A6 O O
, O O
CYP2B6 O O
, O O
CYP2C9 O O
, O O
CYP2D6 O O
, O O
CYP2E1 O O
and O O
CYP3A4/5 O O
( O O
CYP2C19 O O
was O O
not O O
investigated O O
) O O
nor O O
does O O
it O O
induce O O
the O O
activity O O
of O O
CYP1A2 O O
, O O
CYP2D6 O O
, O O
or O O
CYP3A4/5 O O
. O O

Therefore O O
, O O
the O O
potential O O
for O O
clinically O O
significant O O
drug O O
interactions O O
with O O
palonosetron B-drug B-drug
appears O O
to O O
be O O
low O O
. O O

A O O
study O O
in O O
healthy O O
volunteers O O
involving O O
single-dose O O
IV O O
palonosetron B-drug B-drug
( O O
0.75 O O
mg O O
) O O
and O O
steady O O
state O O
oral O O
metoclopramide B-drug B-drug
( O O
10 O O
mg O O
four O O
times O O
daily O O
) O O
demonstrated O O
no O O
significant O O
pharmacokinetic O O
interaction O O
. O O

In O O
controlled O O
clinical O O
trials O O
, O O
ALOXI B-brand B-brand
injection O O
has O O
been O O
safely O O
administered O O
with O O
corticosteroids B-group B-group
, O O
analgesics B-group B-group
, O O
antiemetics/antinauseants B-group B-group
, O O
antispasmodics B-group B-group
and O O
anticholinergic B-group B-group
agents I-group I-group
. O O

Palonosetron B-drug B-drug
did O O
not O O
inhibit O O
the O O
antitumor O O
activity O O
of O O
the O O
five O O
chemotherapeutic B-group O
agents I-group O
tested O O
( O O
cisplatin B-drug B-drug
, O O
cyclophosphamide B-drug B-drug
, O O
cytarabine B-drug B-drug
, O O
doxorubicin B-drug B-drug
and O O
mitomycin B-drug B-drug
C I-drug I-drug
) O O
in O O
murine O O
tumor O O
models O O
. O O

Concomitant O O
administration O O
of O O
a O O
loop B-group B-group
diuretic I-group I-group
had O O
no O O
effect O O
on O O
the O O
calcium-lowering O O
action O O
of O O
Aredia B-brand B-brand
. O O

Caution O O
is O O
indicated O O
when O O
Aredia B-brand B-brand
is O O
used O O
with O O
other O O
potentially O O
nephrotoxic O O
drugs O O
. O O

Also O O
see O O
CLINICAL O O
PHARMACOLOGY O O

No O O
formal O O
drug-drug O O
interaction O O
studies O O
have O O
been O O
conducted O O
with O O
Vectibix B-brand B-brand
. O O

Not O O
compatible O O
with O O
CNS B-group B-group
depressants I-group I-group
or O O
trycyclic B-group B-group
antidepressants I-group I-group

Drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
Macugen B-brand B-brand
. O O

Pegaptanib B-drug B-drug
is O O
metabolized O O
by O O
nucleases O O
and O O
is O O
generally O O
not O O
affected O O
by O O
the O O
cytochrome O O
P450 O O
system O O
. O O

Two O O
early O O
clinical O O
studies O O
conducted O O
in O O
patients O O
who O O
received O O
Macugen B-brand B-brand
alone O O
and O O
in O O
combination O O
with O O
PDT O O
revealed O O
no O O
apparent O O
difference O O
in O O
the O O
plasma O O
pharmacokinetics O O
of O O
pegaptanib B-drug B-drug
. O O

Interactions O O
with O O
cylcopholsphamide O B-drug
, O O
fludarabine B-drug B-drug
and O O
vidarabine B-drug B-drug

Diagnosis O O
of O O
pheochromocytoma O O
- O O
phentolamine O B-drug
blocking O O
test O O
. O O

The O O
test O O
is O O
most O O
reliable O O
in O O
detecting O O
pheochromocytoma O O
in O O
patients O O
with O O
sustained O O
hypertension O O
and O O
least O O
reliable O O
in O O
those O O
with O O
paroxysmal O O
hypertension O O
. O O

False-positive O O
tests O O
may O O
occur O O
in O O
patients O O
with O O
hypertension O O
without O O
pheochromocytoma O O
. O O

Potential O O
interactions O O
between O O
Elidel B-brand B-brand
and O O
other O O
drugs O O
, O O
including O O
immunizations O O
, O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

Due O O
to O O
the O O
very O O
low O O
blood O O
levels O O
of O O
pimecrolimus B-drug B-drug
detected O O
in O O
some O O
patients O O
after O O
topical O O
application O O
, O O
systemic O O
drug O O
interactions O O
are O O
not O O
expected O O
, O O
but O O
can O O
not O O
be O O
ruled O O
out O O
. O O

The O O
concomitant O O
administration O O
of O O
known O O
CYP3A O O
family O O
of O O
inhibitors O O
in O O
patients O O
with O O
widespread O O
and/or O O
erythrodermic O O
disease O O
should O O
be O O
done O O
with O O
caution O O
. O O

Some O O
examples O O
of O O
such O O
drugs O O
are O O
erythromycin B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
fluconazole B-drug B-drug
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
and O O
cimetidine B-drug B-drug
. O O

In O O
vivo O O
drug-drug O O
interaction O O
studies O O
have O O
suggested O O
that O O
pioglitazone B-drug B-drug
may O O
be O O
a O O
weak O O
inducer O O
of O O
CYP O O
450 O O
isoform O O
3A4 O O
substrate O O
. O O

Drug O O
Interactions O O
: O O
Pirenzepine B-drug B-drug
may O O
interact O O
with O O
the O O
following O O
drugs O O
, O O
which O O
may O O
affect O O
the O O
effect O O
of O O
Pirenzepine B-drug B-drug
or O O
whose O O
effects O O
may O O
be O O
affected O O
. O O

- O O
Antacids B-group B-group
- O O
Diarrhea O O
medicine O O
containing O O
kaolin B-drug B-drug
or O O
attapulgite B-drug O
- O O
Ketoconazole B-drug B-drug
- O O
Central B-group B-group
nervous I-group I-group
system I-group I-group
( I-group I-group
CNS I-group I-group
) I-group I-group
depressants I-group I-group
- O O
Other O O
anticholinergics B-group B-group
- O O
Tricyclic B-group B-group
antidepressants I-group I-group
( O O
e.g. O O
, O O
Elavil B-brand B-brand
, O O
Asendin B-brand B-brand
, O O
Anafranil B-brand B-brand
, O O
Pertofrane B-brand B-drug
, O O
Sinequan B-brand B-brand
, O O
Tofranil B-brand B-brand
, O O
Aventyl B-brand B-brand
, O O
Surmontil B-brand B-brand
) O O
- O O
Potassium B-drug B-drug
chloride I-drug I-drug
( O O
e.g. O O
, O O
Kay B-brand O
Ciel I-brand O
) O O

There O O
have O O
been O O
no O O
formal O O
interaction O O
studies O O
of O O
PHOTOFRIN B-brand B-brand
and O O
any O O
other O O
drugs O O
. O O

However O O
, O O
it O O
is O O
possible O O
that O O
concomitant O O
use O O
of O O
other O O
photosensitizing B-group O
agents I-group O
( O O
e.g. O O
, O O
tetracyclines B-group B-group
, O O
sulfonamides B-group B-group
, O O
phenothiazines B-group B-group
, O O
sulfonylurea B-group B-group
hypoglycemia O I-group
agents O I-group
, O O
thiazide B-group B-group
diuretics I-group I-group
, O O
and O O
griseofulvin B-drug B-drug
) O O
could O O
increase O O
the O O
photosensitivity O O
reaction O O
. O O

PHOTOFRIN B-brand B-brand
PDT O O
causes O O
direct O O
intracellular O O
damage O O
by O O
initiating O O
radical O O
chain O O
reactions O O
that O O
damage O O
intracellular O O
membranes O O
and O O
mitochondria O O
. O O

Tissue O O
damage O O
also O O
results O O
from O O
ischemia O O
secondary O O
to O O
vasoconstriction O O
, O O
platelet O O
activation O O
and O O
aggregation O O
and O O
clotting O O
. O O

Research O O
in O O
animals O O
and O O
in O O
cell O O
culture O O
has O O
suggested O O
that O O
many O O
drugs O O
could O O
influence O O
the O O
effects O O
of O O
PDT O O
, O O
possible O O
examples O O
of O O
which O O
are O O
described O O
below O O
. O O

There O O
are O O
no O O
human O O
data O O
that O O
support O O
or O O
rebut O O
these O O
possibilities O O
. O O

Compounds O O
that O O
quench O O
active O O
oxygen O O
species O O
or O O
scavenge O O
radicals O O
, O O
such O O
as O O
dimethyl B-drug_n B-drug_n
sufloxide I-drug_n I-drug_n
, O O
b-carotene B-drug B-drug
, O O
ethanol B-drug B-drug
, O O
formate B-drug_n B-drug
and O O
mannitol B-drug B-drug
would O O
be O O
expected O O
to O O
decrease O O
PDT O O
activity O O
. O O

Preclinical O O
data O O
also O O
suggest O O
that O O
tissue O O
ischemia O O
, O O
allopurinol B-drug B-drug
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
and O O
some O O
prostaglandin O B-group
synthesis O I-group
inhibitors O I-group
could O O
interfere O O
with O O
PHOTOFRIN O B-brand
PDT O O
. O O

Drugs O O
that O O
decrease O O
clotting O O
, O O
vasoconstriction O O
or O O
platelet O O
aggregation O O
, O O
e.g. O O
, O O
thromboxane O B-group
A2 O I-group
inhibitors O I-group
, O O
could O O
decrease O O
the O O
efficacy O O
of O O
PDT O O
. O O

Glucocorticoid B-group B-group
hormones O I-group
given O O
before O O
or O O
concomitant O O
with O O
PDT O O
may O O
decrease O O
the O O
efficacy O O
of O O
the O O
treatment O O
. O O

No O O
data O O
are O O
available O O
regarding O O
interaction O O
of O O
BILTRICIDE B-brand B-brand
with O O
other O O
drugs O O
. O O

May O O
increase O O
the O O
effect O O
of O O
oral O O
blood B-group B-group
thinners I-group I-group
, O O
for O O
example O O
warfarin B-drug B-drug
( O O
Coumadin B-brand B-brand
) O O
. O O

Therefore O O
, O O
warfarin B-drug B-drug
dose O O
changes O O
and O O
monitoring O O
for O O
the O O
effects O O
of O O
warfarin B-drug B-drug
on O O
blood O O
clotting O O
are O O
necessary O O
. O O

Pyrazinamide B-drug B-drug
has O O
been O O
reported O O
to O O
interfere O O
with O O
ACETEST O B-brand
and O O
KETOSTIX O B-brand
urine O O
tests O O
to O O
produce O O
a O O
pink-brown O O
color O O
. O O

5 O O

Alcohol B-drug B-drug
( O O
this O O
combination O O
may O O
make O O
you O O
very O O
sick O O
) O O
and O O
primaquine B-drug B-drug

Drug O O
interaction O O
studies O O
have O O
not O O
been O O
conducted O O
with O O
LUCENTIS B-brand B-brand
. O O

LUCENTIS B-brand B-brand
intravitreal O O
injection O O
has O O
been O O
used O O
adjunctively O O
with O O
verteporfin B-drug B-drug
photodynamic O O
therapy O O
( O O
PDT O O
) O O
. O O

Twelve O O
of O O
105 O O
( O O
11 O O
% O O
) O O
patients O O
developed O O
serious O O
intraocular O O
inflammation O O
; O O

in O O
10 O O
of O O
the O O
12 O O
patients O O
, O O
this O O
occurred O O
when O O
LUCENTIS B-brand B-brand
was O O
administered O O
7 O O
days O O
( O O
2 O O
days O O
) O O
after O O
verteporfin B-drug B-drug
PDT O O
. O O

Combined O O
usage O O
of O O
MAO B-group B-group
inhibitors I-group I-group
should O O
be O O
avoided O O

In O O
animals O O
the O O
duration O O
of O O
muscle O O
paralysis O O
from O O
succinylcholine B-drug B-drug
is O O
not O O
prolonged O O
by O O
remifentanil B-drug O
. O O

Remifentanil B-drug O
clearance O O
is O O
not O O
altered O O
by O O
concomitant O O
administration O O
of O O
thiopental B-drug B-drug
, O O
isoflurane B-drug B-drug
, O O
propofol B-drug B-drug
, O O
or O O
temazepam B-drug B-drug
during O O
anesthesia O O
. O O

In O O
vitro O O
studies O O
with O O
atracurium B-drug B-drug
, O O
mivacurium B-drug B-drug
, O O
esmolol B-drug B-drug
, O O
echothiophate B-drug B-drug_n
, O O
neostigmine B-drug O
, O O
physostigmine B-drug B-drug
, O O
and O O
midazolam B-drug B-drug
revealed O O
no O O
inhibition O O
of O O
remifentanil B-drug O
hydrolysis O O
in O O
whole O O
human O O
blood O O
by O O
these O O
drugs O O
. O O

There O O
are O O
, O O
as O O
yet O O
, O O
no O O
known O O
drug O O
interactions O O
, O O
but O O
further O O
study O O
is O O
required O O
. O O

Clinical O O
studies O O
of O O
interactions O O
of O O
VIRAZOLE B-brand B-brand
with O O
other O O
drugs O O
commonly O O
used O O
to O O
treat O O
infants O O
with O O
RSV O O
infections O O
, O O
such O O
as O O
digoxin B-drug B-drug
, O O
bronchodilators B-group B-group
, O O
other O O
antiviral B-group B-group
agents I-group I-group
, O O
antibiotics B-group B-group
, O O
or O O
anti-metabolites B-group B-group
have O O
not O O
been O O
conducted O O
. O O

Interference O O
by O O
VIRAZOLE B-brand B-brand
with O O
laboratory O O
tests O O
has O O
not O O
been O O
evaluated O O
. O O

Drug-Drug O O
Interactions O O
Although O O
in O O
vitro O O
studies O O
demonstrated O O
the O O
potential O O
of O O
rifaximin B-drug B-drug
to O O
interact O O
with O O
cytochrome O O
P450 O O
3A4 O O
( O O
CYP3A4 O O
) O O
, O O
a O O
clinical O O
drug-drug O O
interaction O O
study O O
demonstrated O O
that O O
rifaximin B-drug B-drug
did O O
not O O
significantly O O
affect O O
the O O
pharmacokinetics O O
of O O
midazolam B-drug B-drug
either O O
presystemically O O
or O O
systemically O O
. O O

An O O
additional O O
clinical O O
drug-drug O O
interaction O O
study O O
showed O O
no O O
effect O O
of O O
rifaximin B-drug B-drug
on O O
the O O
presystemic O O
metabolism O O
of O O
an O O
oral O O
contraceptive B-group B-group
containing O O
ethinyl B-drug B-drug
estradiol I-drug I-drug
and O O
norgestimate B-drug B-drug
. O O

Therefore O O
, O O
clinical O O
interactions O O
with O O
drugs O O
metabolized O O
by O O
human O O
cytochrome O O
P450 O O
isoenzymes O O
are O O
not O O
expected O O
. O O

Drug/Laboratory O O
Interactions O O
: O O
There O O
have O O
been O O
no O O
formal O O
drug O O
interaction O O
studies O O
performed O O
with O O
RITUXAN B-brand B-brand
. O O

However O O
, O O
renal O O
toxicity O O
was O O
seen O O
with O O
this O O
drug O O
in O O
combination O O
with O O
cisplatin B-drug B-drug
in O O
clinical O O
trials O O
. O O

There O O
are O O
so O O
far O O
no O O
reported O O
adverse O O
interactions O O
with O O
SAMe B-drug O
and O O
other O O
drugs O O
, O O
dietary O O
supplements O O
or O O
foods O O
. O O

Drug/Laboratory O O
Test O O
Interaction O O
: O O
The O O
concomitant O O
use O O
of O O
anticholinergic B-group B-group
agents I-group I-group
may O O
make O O
patients O O
hyporesponsive O O
, O O
i.e O O
. O O

may O O
produce O O
a O O
false O O
positive O O
result O O
. O O

Concomitant O O
glucocorticoid O B-group
therapy O O
may O O
inhibit O O
the O O
response O O
to O O
Geref B-brand O
. O O
There O O
was O O
no O O
evidence O O
in O O
the O O
controlled O O
studies O O
of O O
Geref B-brand B-brand
's O O
interaction O O
with O O
drugs O O
commonly O O
used O O
in O O
the O O
treatment O O
of O O
routine O O
pediatric O O
problems/illnesses O O
. O O

However O O
, O O
formal O O
drug O O
interactions O O
studies O O
have O O
not O O
been O O
conducted O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
: O O
Potential O O
interactions O O
between O O
ERTACZOTM B-brand B-brand
Cream O O
, O O
2 O O
% O O
, O O
and O O
other O O
drugs O O
or O O
laboratory O O
tests O O
have O O
not O O
been O O
systematically O O
evaluated O O
. O O

Interactions O O
for O O
Sodium B-drug B-drug
Tetradecyl I-drug I-drug
Sulfate I-drug I-drug
: O O
No O O
well-controlled O O
studies O O
have O O
been O O
performed O O
on O O
patients O O
taking O O
antiovulatory O B-group
agents O I-group
. O O

The O O
physician O O
must O O
use O O
judgment O O
and O O
evaluate O O
any O O
patient O O
taking O O
antiovulatory O B-group
drugs O I-group
prior O O
to O O
initiating O O
treatment O O
with O O
Sotradecol B-brand B-brand
. O O

Heparin B-drug B-drug
should O O
not O O
be O O
included O O
in O O
the O O
same O O
syringe O O
as O O
Sodium B-drug B-drug
Tetradecyl I-drug I-drug
Sulfate I-drug I-drug
, O O
since O O
the O O
two O O
are O O
incompatible O O
. O O

Digoxin B-drug B-drug
: O O
Sparfloxacin B-drug B-drug
has O O
no O O
effect O O
on O O
the O O
pharmacokinetics O O
of O O
digoxin B-drug B-drug
. O O

Methylxanthines B-group B-group
: O O
Sparfloxacin B-drug B-drug
does O O
not O O
increase O O
plasma O O
theophylline B-drug B-drug
concentrations O O
. O O

Since O O
there O O
is O O
no O O
interaction O O
with O O
theophylline B-drug B-drug
, O O
interaction O O
with O O
other O O
methylxanthines B-group B-group
such O O
as O O
caffeine B-drug B-drug
is O O
unlikely O O
. O O

Warfarin B-drug B-drug
: O O
Sparfloxacin B-drug B-drug
does O O
not O O
increase O O
the O O
anti-coagulant O O
effect O O
of O O
warfarin B-drug B-drug
. O O

Cimetidine B-drug B-drug
: O O
Cimetidine B-drug B-drug
does O O
not O O
affect O O
the O O
pharmacokinetics O O
of O O
sparfloxacin B-drug B-drug
. O O

The O O
oral O O
bioavailability O O
of O O
sparfloxacin B-drug B-drug
is O O
not O O
reduced O O
when O O
the O O
aluminum-magnesium B-drug B-drug
suspension O O
is O O
administered O O
4 O O
hours O O
following O O
sparfloxacin O B-drug
administration O O
. O O

Zinc/iron B-drug B-drug
salts O O
: O O
Absorption O O
of O O
quinolones B-group B-group
is O O
reduced O O
significantly O O
by O O
these O O
preparations O O
. O O

These O O
products O O
may O O
be O O
taken O O
4 O O
hours O O
after O O
sparfloxacin B-drug B-drug
administration O O
. O O

Probenecid B-drug B-drug
: O O
Probenecid B-drug B-drug
does O O
not O O
alter O O
the O O
pharmacokinetics O O
of O O
sparfloxacin B-drug B-drug
. O O

This O O
medicine O O
is O O
generally O O
safe O O
with O O
other O O
medications O O
, O O
but O O
patient O O
should O O
consult O O
doctor O O
or O O
pharmacist O O
if O O
patient O O
is O O
taking O O
a O O
blood O B-group
thinner O I-group
( O O
anticoagulant B-group B-group
) O O
, O O
cyclosporin B-drug B-drug
, O O
phenytoin B-drug B-drug
, O O
or O O
methotrexate B-drug B-drug
. O O

Formal O O
topical O O
drug O O
interaction O O
studies O O
with O O
PROTOPIC B-brand B-brand
Ointment O O
have O O
not O O
been O O
conducted O O
. O O

Based O O
on O O
its O O
minimal O O
extent O O
of O O
absorption O O
, O O
interactions O O
of O O
PROTOPIC B-brand B-brand
Ointment O O
with O O
systemically O O
administered O O
drugs O O
are O O
unlikely O O
to O O
occur O O
but O O
can O O
not O O
be O O
ruled O O
out O O
. O O

The O O
concomitant O O
administration O O
of O O
known O O
CYP3A4 O O
inhibitors O O
in O O
patients O O
with O O
widespread O O
and/or O O
erythrodermic O O
disease O O
should O O
be O O
done O O
with O O
caution O O
. O O

Some O O
examples O O
of O O
such O O
drugs O O
are O O
erythromycin B-drug B-drug
, O O
itraconazole B-drug B-drug
, O O
ketoconazole B-drug B-drug
, O O
fluconazole B-drug B-drug
, O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
and O O
cimetidine B-drug B-drug
. O O

Telbivudine B-drug B-drug
is O O
excreted O O
mainly O O
by O O
passive O O
diffusion O O
so O O
the O O
potential O O
for O O
interactions O O
between O O
telbivudine B-drug B-drug
and O O
other O O
drugs O O
eliminated O O
by O O
renal O O
excretion O O
is O O
low O O
. O O

However O O
, O O
because O O
telbivudine B-drug B-drug
is O O
eliminated O O
primarily O O
by O O
renal O O
excretion O O
, O O
co O O
administration O O
of O O
telbivudine B-drug B-drug
with O O
drugs O O
that O O
alter O O
renal O O
function O O
may O O
alter O O
plasma O O
concentrations O O
of O O
telbivudine B-drug B-drug
. O O

The O O
pharmacokinetic O O
profile O O
of O O
temazepam B-drug B-drug
does O O
not O O
appear O O
to O O
be O O
altered O O
by O O
orally O O
administered O O
cimetidine B-drug B-drug
dosed O O
according O O
to O O
labeling O O
. O O

TERAZOL B-brand B-brand
7 O O
Vaginal O O
Cream O O
0.4 O O
% O O
and O O
TERAZOL B-brand B-brand
3 O O
Vaginal O O
Suppositories O O
80 O O
mg O O
The O O
therapeutic O O
effect O O
of O O
these O O
products O O
is O O
not O O
affected O O
by O O
oral O O
contraceptive B-group B-group
usage O O
. O O

TERAZOL B-brand B-brand
3 O O
Vaginal O O
Cream O O
0.8 O O
% O O
The O O
levels O O
of O O
estradiol B-drug B-drug
( O O
E2 O O
) O O
and O O
progesterone B-drug B-drug
did O O
not O O
differ O O
significantly O O
when O O
0.8 O O
% O O
terconazole B-drug B-drug
vaginal O O
cream O O
was O O
administered O O
to O O
healthy O O
female O O
volunteers O O
established O O
on O O
a O O
low O O
dose O O
oral O O
contraceptive B-group B-group
. O O

Interactions O O
Interaction O O
may O O
occur O O
with O O
Antacids B-group B-group
, O O
Calcium B-drug B-drug
supplements O O
, O O
Cholestyramine B-drug B-drug
, O O
Choline B-drug B-drug
and O O
magnesium B-drug B-drug
salicylates I-drug B-group
, O O
Colestipol B-drug B-drug
, O O
Iron-containing B-drug B-group
drugs O I-group
, O O
Laxatives B-group B-group
, O O
Magnesium B-drug B-drug
salicylate I-drug I-drug
: O O
these O O
drugs O O
may O O
decrease O O
the O O
potency O O
of O O
tetracyclines B-group B-group
. O O

Oral O O
contraceptives B-group B-group
containing O O
estrogen B-drug B-group
: O O
tetracyclines B-group B-group
may O O
decrease O O
the O O
contraceptive O O
effect O O
and O O
increase O O
the O O
chance O O
of O O
unwanted O O
pregnancy O O
. O O

No O O
formal O O
drug O O
interaction O O
studies O O
have O O
been O O
performed O O
. O O

Due O O
to O O
the O O
frequent O O
occurrence O O
of O O
severe O O
and O O
prolonged O O
thrombocytopenia O O
, O O
the O O
potential O O
benefits O O
of O O
medications O O
that O O
interfere O O
with O O
platelet O O
function O O
and/or O O
anticoagulation O O
should O O
be O O
weighed O O
against O O
the O O
potential O O
increased O O
risk O O
of O O
bleeding O O
and O O
hemorrhage O O
. O O

Drug/Laboratory O O
Test O O
Interactions O O
Administration O O
of O O
the O O
BEXXAR B-brand B-brand
therapeutic O O
regimen O O
may O O
result O O
in O O
the O O
development O O
of O O
human O O
anti-murine O B-group
antibodies O I-group
( O O
HAMA O O
) O O
. O O

The O O
presence O O
of O O
HAMA O O
may O O
affect O O
the O O
accuracy O O
of O O
the O O
results O O
of O O
in O O
vitro O O
and O O
in O O
vivo O O
diagnostic O O
tests O O
and O O
may O O
affect O O
the O O
toxicity O O
profile O O
and O O
efficacy O O
of O O
therapeutic O O
agents O O
that O O
rely O O
on O O
murine O O
antibody O O
technology O O
. O O

Patients O O
who O O
are O O
HAMA O O
positive O O
may O O
be O O
at O O
increased O O
risk O O
for O O
serious O O
allergic O O
reactions O O
and O O
other O O
side O O
effects O O
if O O
they O O
undergo O O
in O O
vivo O O
diagnostic O O
testing O O
or O O
treatment O O
with O O
murine B-group B-group
monoclonal I-group I-group
antibodies I-group I-group
. O O

Because O O
systemic O O
exposure O O
to O O
Valstar B-brand B-brand
is O O
negligible O O
following O O
intravesical O O
administration O O
, O O
the O O
potential O O
for O O
drug O O
interactions O O
is O O
low O O
. O O

No O O
drug O O
interaction O O
studies O O
were O O
conducted O O
. O O

Dosage O O
adjustment O O
should O O
be O O
based O O
on O O
serial O O
blood O O
level O O
monitoring O O
. O O

The O O
contribution O O
of O O
vincristine B-drug B-drug
sulfate I-drug I-drug
to O O
this O O
interaction O O
is O O
not O O
certain O O
. O O

The O O
interaction O O
may O O
result O O
from O O
reduced O O
absorption O O
of O O
phenytoin B-drug B-drug
and O O
an O O
increase O O
in O O
the O O
rate O O
of O O
its O O
metabolism O O
and O O
elimination O O
. O O

- O O
Increased O O
action O O
of O O
oral O O
anticoagulants B-group B-group
. O O

- O O
Decreased O O
absorption O O
of O O
colestipol B-drug B-drug
, O O
cholestyramine B-drug B-drug
, O O
mineral B-drug B-drug_n
oil I-drug I-drug_n
, O O
and O O
sucralfate B-drug B-drug
. O O

Single-dose O O
bioequivalence O O
of O O
105-mg O O
fenofibric B-drug O
acid I-drug O
tablets O O
versus O O
145-mg O O
fenofibrate B-drug B-drug
tablets O O
under O O
fasting O O
and O O
fed O O
conditions O O
: O O
a O O
report O O
of O O
two O O
phase O O
I O O
, O O
open-label O O
, O O
single-dose O O
, O O
randomized O O
, O O
crossover O O
clinical O O
trials O O
. O O

Fenofibrate B-drug B-drug
is O O
used O O
to O O
treat O O
primary O O
hypercholesterolemia O O
, O O
mixed O O
lipidemia O O
, O O
and O O
hypertriglyceridemia O O
in O O
adults O O
who O O
do O O
not O O
respond O O
to O O
nonpharmacologic O O
measures O O
. O O

Fenofibrate B-drug B-drug
is O O
a O O
prodrug O O
that O O
is O O
rapidly O O
and O O
completely O O
hydrolyzed O O
to O O
fenofibric B-drug_n B-drug_n
acid I-drug_n I-drug_n
, O O
the O O
active O O
moiety O O
. O O

A O O
new O O
orally O O
administered O O
agent O O
, O O
fenofibric B-drug B-drug
acid I-drug I-drug
, O O
was O O
developed O O
as O O
an O O
alternative O O
to O O
fenofibrate B-drug B-drug
. O O

Two O O
separate O O
studies O O
were O O
conducted O O
to O O
evaluate O O
the O O
bioequivalence O O
of O O
fenofibric B-drug O
acid I-drug O
relative O O
to O O
fenofibrate B-drug B-drug
under O O
fasted O O
and O O
fed O O
( O O
standard O O
breakfast O O
) O O
conditions O O
, O O
characterize O O
the O O
pharmacokinetic O O
profile O O
, O O
and O O
assess O O
the O O
safety O O
and O O
tolerability O O
of O O
fenofibric B-drug B-drug
acid I-drug I-drug
. O O

In O O
study O O
1 O O
( O O
fasted O O
) O O
, O O
during O O
each O O
study O O
period O O
, O O
volunteers O O
received O O
a O O
single O O
105-mg O O
dose O O
of O O
fenofibric B-drug B-drug
acid I-drug I-drug
or O O
single O O
145-mg O O
dose O O
of O O
fenofibrate B-drug B-drug
( O O
depending O O
on O O
their O O
randomization O O
scheme O O
) O O
after O O
an O O
overnight O O
fast O O
( O O
a O O
minimum O O
fast O O
of O O
10 O O
hours O O
) O O
. O O

A O O
7-day O O
washout O O
period O O
followed O O
the O O
first O O
treatment O O
period O O
, O O
after O O
which O O
the O O
volunteers O O
received O O
the O O
alternate O O
treatment O O
. O O

Study O O
2 O O
followed O O
a O O
similar O O
dosing O O
scheme O O
and O O
differed O O
only O O
in O O
that O O
volunteers O O
received O O
their O O
single O O
dose O O
after O O
being O O
fed O O
a O O
standard O O
meal O O
( O O
575 O O
calories O O
, O O
of O O
which O O
36 O O
% O O
were O O
contributed O O
by O O
fat O O
) O O
. O O

Serial O O
blood O O
samples O O
in O O
both O O
studies O O
were O O
collected O O
up O O
to O O
72 O O
hours O O
after O O
drug O O
administration O O
. O O

The O O
pharmacokinetic O O
parameters O O
of O O
interest O O
for O O
assessing O O
bioequivalence O O
were O O
AUC O O
( O O
0-t O O
) O O
, O O
AUC O O
( O O
0- O O
) O O
, O O
C O O
( O O
max O O
) O O
, O O
and O O
T O O
( O O
max O O
) O O
. O O

The O O
criterion O O
for O O
a O O
lack O O
of O O
difference O O
between O O
products O O
was O O
a O O
90 O O
% O O
CI O O
between O O
0.80 O O
and O O
1.25 O O
for O O
the O O
fenofibric B-drug O
acid I-drug O
: O O
fenofibrate B-drug B-drug
ratios O O
for O O
AUC O O
( O O
0-t O O
) O O
, O O
AUC O O
( O O
0- O O
) O O
, O O
and O O
C O O
( O O
max O O
. O O
) O O

Tolerability O O
was O O
assessed O O
by O O
adverse O O
events O O
( O O
AEs O O
) O O
, O O
laboratory O O
parameters O O
, O O
vital O O
signs O O
, O O
and O O
physical O O
examinations O O
. O O

Volunteers O O
in O O
study O O
1 O O
( O O
fasted O O
; O O
n O O
= O O
54 O O
) O O
were O O
aged O O
18 O O
to O O
43 O O
years O O
; O O

19 O O
( O O
35 O O
% O O
) O O
were O O
men O O
and O O
35 O O
( O O
65 O O
% O O
) O O
were O O
women O O
; O O

mean O O
weight O O
was O O
155.2 O O
pounds O O
( O O
range O O
, O O
103.0-267.0 O O
pounds O O
) O O
; O O

and O O
48 O O
( O O
89 O O
% O O
) O O
were O O
white O O
, O O
1 O O
( O O
2 O O
% O O
) O O
was O O
black O O
, O O
and O O
5 O O
( O O
9 O O
% O O
) O O
were O O
white/American O O
Indian/Alaskan O O
native/Asian O O
. O O

Volunteers O O
in O O
study O O
2 O O
( O O
fed O O
; O O
n O O
= O O
54 O O
) O O
were O O
aged O O
18 O O
to O O
43 O O
years O O
; O O

27 O O
( O O
50 O O
% O O
) O O
were O O
men O O
and O O
27 O O
( O O
50 O O
% O O
) O O
were O O
women O O
; O O

mean O O
weight O O
was O O
161.9 O O
pounds O O
( O O
range O O
, O O
112.0-225.0 O O
pounds O O
) O O
; O O

and O O
51 O O
( O O
94 O O
% O O
) O O
were O O
white O O
( O O
including O O
2 O O
Hispanic O O
) O O
and O O
3 O O
( O O
6 O O
% O O
) O O
were O O
black O O
. O O

The O O
90 O O
% O O
CIs O O
about O O
the O O
ratio O O
of O O
the O O
fenofibric B-drug O
acid I-drug O
geometric O O
mean O O
to O O
the O O
fenofibrate B-drug B-drug
geometric O O
mean O O
were O O
within O O
the O O
80 O O
% O O
and O O
125 O O
% O O
limits O O
for O O
the O O
pharmacokinetic O O
parameters O O
C O O
( O O
max O O
) O O
, O O
AUC O O
( O O
0-t O O
) O O
, O O
and O O
AUC O O
( O O
0- O O
) O O
of O O
the O O
ln-transformed O O
data O O
in O O
both O O
study O O
1 O O
( O O
fasted O O
) O O
and O O
study O O
2 O O
. O O

In O O
study O O
1 O O
( O O
fasted O O
) O O
, O O
14 O O
volunteers O O
( O O
26 O O
% O O
) O O
experienced O O
a O O
total O O
of O O
29 O O
AEs O O
; O O

the O O
most O O
common O O
nonlaboratory O O
AEs O O
were O O
dizziness O O
( O O
6 O O
% O O
) O O
and O O
headache O O
( O O
4 O O
% O O
) O O
. O O

In O O
study O O
2 O O
, O O
12 O O
volunteers O O
( O O
22 O O
% O O
) O O
experienced O O
a O O
total O O
of O O
19 O O
AEs O O
; O O

the O O
most O O
common O O
nonlaboratory O O
AEs O O
were O O
headache O O
( O O
17 O O
% O O
) O O
and O O
dry O O
throat O O
( O O
4 O O
% O O
) O O
. O O

AEs O O
were O O
generally O O
mild O O
or O O
moderate O O
in O O
intensity O O
. O O

In O O
these O O
2 O O
single-dose O O
studies O O
, O O
these O O
healthy O O
volunteers O O
administered O O
a O O
single O O
oral O O
dose O O
of O O
105-mg O O
fenofibric B-drug O
acid I-drug O
met O O
the O O
US O O
Food O O
and O O
Drug O O
Administration O O
regulatory O O
criteria O O
for O O
assuming O O
bioequivalence O O
to O O
a O O
single O O
oral O O
dose O O
of O O
145-mg O O
fenofibrate B-drug B-drug
tablets O O
with O O
respect O O
to O O
the O O
rate O O
and O O
extent O O
of O O
fenofibric B-drug B-drug_n
acid I-drug I-drug_n
absorption O O
in O O
both O O
fed O O
and O O
fasted O O
states O O
. O O

Fenofibric B-drug B-drug
acid I-drug I-drug
at O O
the O O
dose O O
studied O O
was O O
well O O
tolerated O O
in O O
this O O
population O O
. O O

Polypharmacy O O
in O O
older O O
adults O O
. O O

This O O
article O O
explores O O
the O O
issue O O
of O O
polypharmacy O O
in O O
older O O
adults O O
. O O

The O O
physiological O O
changes O O
in O O
organ O O
function O O
in O O
older O O
people O O
and O O
the O O
effect O O
of O O
this O O
on O O
pharmacokinetics O O
and O O
pharmacodynamics O O
are O O
discussed O O
. O O

The O O
risks O O
of O O
adverse O O
drug O O
reactions O O
and O O
adverse O O
drug O O
interactions O O
linked O O
to O O
polypharmacy O O
are O O
explored O O
. O O

Strategies O O
to O O
achieve O O
optimal O O
prescribing O O
in O O
older O O
people O O
are O O
considered O O
. O O

Tuberculosis O O
and O O
HIV O O
co-infection O O
: O O
screening O O
and O O
treatment O O
strategies O O
. O O

Globally O O
, O O
tuberculosis O O
( O O
TB O O
) O O
and O O
HIV O O
interact O O
in O O
deadly O O
synergy O O
. O O

The O O
high O O
burden O O
of O O
TB O O
among O O
HIV-infected O O
individuals O O
underlies O O
the O O
importance O O
of O O
TB O O
diagnosis O O
, O O
treatment O O
and O O
prevention O O
for O O
clinicians O O
involved O O
in O O
HIV O O
care O O
. O O

Despite O O
expanding O O
access O O
to O O
antiretroviral B-group B-group
therapy O O
( O O
ART O O
) O O
to O O
treat O O
HIV O O
infection O O
in O O
resource-limited O O
settings O O
, O O
many O O
individuals O O
in O O
need O O
of O O
therapy O O
initiate O O
ART O O
too O O
late O O
and O O
have O O
already O O
developed O O
clinically O O
significant O O
TB O O
by O O
the O O
time O O
they O O
present O O
for O O
care O O
. O O

Many O O
co-infected O O
individuals O O
are O O
in O O
need O O
of O O
concurrent O O
ART O O
and O O
anti-TB O O
therapy O O
, O O
which O O
dramatically O O
improves O O
survival O O
, O O
but O O
also O O
raises O O
several O O
management O O
challenges O O
, O O
including O O
drug O O
interactions O O
, O O
shared O O
drug O O
toxicities O O
and O O
TB O O
immune O O
reconstitution O O
inflammatory O O
syndrome O O
( O O
IRIS O O
) O O
. O O

Due O O
to O O
the O O
survival O O
benefits O O
of O O
promptly O O
initiating O O
ART O O
among O O
all O O
HIV-infected O O
individuals O O
, O O
including O O
those O O
with O O
TB O O
, O O
it O O
is O O
recommended O O
that O O
co-infected O O
individuals O O
receive O O
treatment O O
for O O
both O O
diseases O O
, O O
regardless O O
of O O
CD4+ O O
cell O O
count O O
. O O

We O O
review O O
current O O
screening O O
and O O
treatment O O
strategies O O
for O O
TB O O
and O O
HIV O O
co-infection O O
. O O

Recent O O
findings O O
and O O
ongoing O O
studies O O
will O O
assist O O
clinicians O O
in O O
managing O O
the O O
prevention O O
and O O
treatment O O
of O O
TB O O
and O O
HIV O O
co-infection O O
, O O
which O O
remains O O
a O O
major O O
global O O
health O O
challenge O O
. O O

Older O O
adults O O
with O O
multi-morbidity O O
: O O
medication O O
management O O
processes O O
and O O
design O O
implications O O
for O O
personal O O
health O O
applications O O
. O O

Older O O
adults O O
often O O
have O O
multiple O O
chronic O O
problems O O
requiring O O
them O O
to O O
manage O O
complex O O
medication O O
regimens O O
overseen O O
by O O
various O O
clinicians O O
. O O

Personal O O
health O O
applications O O
( O O
PHAs O O
) O O
show O O
promise O O
assisting O O
in O O
medication O O
self-management O O
, O O
but O O
adoption O O
of O O
new O O
computer O O
technologies O O
by O O
this O O
population O O
is O O
challenging O O
. O O

Optimizing O O
the O O
utility O O
of O O
PHAs O O
requires O O
a O O
thorough O O
understanding O O
of O O
older O O
adults O O
' O O
needs O O
, O O
preferences O O
, O O
and O O
practices O O
. O O

Flow O O
cytometry-based O O
pharmacodynamic O O
monitoring O O
after O O
organ O O
transplantation O O
. O O

Conventional O O
therapeutic O O
drug O O
monitoring O O
based O O
on O O
measuring O O
immunosupressive B-group O
drug I-group O
concentrations O O
in O O
blood O O
is O O
important O O
in O O
the O O
clinical O O
management O O
of O O
immunosuppressive B-group B-group
therapy O O
in O O
transplantation O O
medicine O O
. O O

Since O O
rejection O O
or O O
infection O O
occurs O O
at O O
irregular O O
drug O O
concentrations O O
immunosuppressive B-group B-group
drug I-group I-group
therapy O O
is O O
often O O
empiric O O
and O O
prophylactic O O
in O O
nature O O
. O O

In O O
addition O O
, O O
blood O O
immunosuppressant B-group B-group
levels O O
are O O
only O O
indirect O O
predictors O O
of O O
the O O
pharmacologic O O
effects O O
on O O
immune O O
cells O O
, O O
because O O
the O O
genetic O O
heterogeneity O O
the O O
immune O O
systems O O
of O O
transplant O O
recipients O O
are O O
not O O
equally O O
sensitive O O
to O O
drug O O
effects O O
. O O

Therefore O O
, O O
therapeutic O O
drug O O
monitoring O O
requires O O
the O O
application O O
of O O
reliable O O
and O O
effective O O
methods O O
to O O
study O O
the O O
pharmacodynamic O O
variability O O
by O O
direct O O
measurements O O
of O O
drug O O
effects O O
on O O
immune O O
cell O O
functions O O
. O O

Flow O O
cytometry O O
offers O O
a O O
multiplicity O O
of O O
quantitative O O
analysis O O
possibilities O O
, O O
from O O
detection O O
of O O
phosphorylated O O
molecules O O
up O O
to O O
complex O O
multicolor O O
analysis O O
of O O
whole O O
blood O O
samples O O
. O O

A O O
large O O
spectrum O O
of O O
flow O O
cytometry-based O O
applications O O
for O O
pharmacodynamic O O
monitoring O O
is O O
available O O
and O O
allows O O
detection O O
and O O
analysis O O
of O O
diverse O O
function O O
of O O
T O O
cells O O
and O O
dendritic O O
cell O O
subsets O O
. O O

By O O
combining O O
several O O
assays O O
, O O
it O O
is O O
possible O O
to O O
generate O O
a O O
broad O O
picture O O
of O O
the O O
immune O O
status O O
of O O
every O O
single O O
transplanted O O
recipient O O
. O O

Furthermore O O
, O O
it O O
is O O
even O O
possible O O
to O O
differentiate O O
between O O
synergistic O O
and O O
antagonistic O O
pharmacodynamic O O
effects O O
of O O
immunosuppressive B-group B-group
drug I-group I-group
combination O O
therapy O O
in O O
vitro O O
and O O
to O O
predict O O
the O O
pharmacodynamic O O
drug O O
effects O O
in O O
transplanted O O
recipients O O
. O O

Such O O
a O O
pharmacodynamic O O
drug O O
monitoring O O
may O O
offer O O
the O O
opportunity O O
to O O
complete O O
conventional O O
therapeutic O O
drug O O
monitoring O O
and O O
, O O
therefore O O
, O O
to O O
tailor O O
immunosuppressive B-group B-group
therapy O O
more O O
individually O O
. O O

[ O O
Tuberculosis O O
and O O
HIV O O
- O O
features O O
of O O
the O O
co-infection O O
] O O
. O O

The O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
epidemic O O
has O O
allowed O O
the O O
incidence O O
of O O
tuberculosis O O
to O O
rise O O
globally O O
and O O
particularly O O
in O O
sub-Saharan O O
Africa O O
. O O

Diagnosis O O
and O O
treatment O O
of O O
tuberculosis O O
is O O
more O O
complex O O
in O O
patients O O
with O O
HIV/AIDS O O
. O O

Sputum O O
smear O O
microscopy O O
is O O
performing O O
poorly O O
in O O
HIV-infected O O
individuals O O
, O O
who O O
are O O
often O O
started O O
on O O
antituberculosis O O
treatment O O
on O O
clinical O O
grounds O O
. O O

The O O
treatment O O
of O O
coinfected O O
patients O O
requires O O
antituberculosis B-group O
and O O
antiretroviral B-group B-group
drugs I-group I-group
to O O
be O O
administered O O
concomittantly O O
; O O

challenges O O
include O O
pill O O
burden O O
and O O
patient O O
compliance O O
, O O
drug O O
interactions O O
, O O
overlapping O O
toxic O O
effects O O
, O O
and O O
immune O O
reconstitution O O
inflammatory O O
syndrome O O
. O O

Current O O
guidelines O O
recommend O O
starting O O
antiretroviral B-group B-group
treatment O O
within O O
a O O
few O O
weeks O O
of O O
antituberculosis B-group O
therapy O O
for O O
patients O O
with O O
CD4 O O
cell O O
counts O O

350 O O
cells/ul O O
. O O

[ O O
Medical O O
treatment O O
of O O
tuberculosis O O
- O O
update O O
2011 O O
] O O
. O O

Tuberculosis O O
is O O
the O O
second O O
most O O
common O O
cause O O
of O O
death O O
from O O
an O O
infectious O O
disease O O
after O O
HIV/AIDS O O
and O O
the O O
leading O O
cause O O
of O O
death O O
from O O
an O O
infectious O O
disease O O
in O O
HIV-co-infected O O
patients O O
. O O

Currently O O
, O O
drug O O
susceptible O O
TB O O
is O O
treated O O
with O O
a O O
four O O
drug O O
regimen O O
given O O
over O O
a O O
period O O
of O O
two O O
months O O
followed O O
by O O
two O O
drugs O O
for O O
four O O
months O O
. O O

Drug O O
resistant O O
tuberculosis O O
requires O O
more O O
complex O O
and O O
longer O O
treatment O O
with O O
alternative O O
substances O O
. O O

New O O
antituberculosis B-group O
drugs I-group O
are O O
currently O O
being O O
developed O O
and O O
investigated O O
and O O
are O O
urgently O O
needed O O
to O O
treat O O
drug O O
susceptible O O
and O O
drug O O
resistant O O
TB O O
. O O

Effects O O
of O O
neferine B-drug_n B-drug
on O O
the O O
pharmacokinetics O O
of O O
amiodarone B-drug B-drug
in O O
rats O O
. O O

Amiodarone B-drug B-drug
, O O
an O O
iodinated O B-group
benzofuran O I-group
derivative O I-group
with O O
predominantly O O
class O O
III O O
anti-arrhythmic O O
effects O O
, O O
is O O
used O O
to O O
treat O O
supraventricular O O
and O O
ventricular O O
arrhythmias O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
assess O O
the O O
potential O O
of O O
neferine B-drug_n B-drug
, O O
an O O
effective O O
anti-pulmonary O O
fibrosis O O
drug O O
isolated O O
from O O
the O O
embryo O O
of O O
Nelumbo O O
nucifera O O
Gaertner O O
's O O
seeds O O
, O O
to O O
alter O O
the O O
pharmacokinetic O O
profile O O
of O O
amiodarone B-drug B-drug
. O O

Experimental O O
Sprague-Dawley O O
rats O O
were O O
randomly O O
divided O O
into O O
two O O
groups O O
. O O

In O O
groups O O
1 O O
and O O
2 O O
, O O
amiodarone B-drug B-drug
was O O
given O O
to O O
rats O O
by O O
intragastric O O
and O O
intravenous O O
administration O O
, O O
respectively O O
, O O
while O O
neferine B-drug_n O
was O O
co-administratered O O
by O O
intragastric O O
administration O O
. O O

Blood O O
samples O O
were O O
collected O O
from O O
the O O
orbital O O
venous O O
plexus O O
at O O
indicated O O
time O O
points O O
and O O
were O O
analyzed O O
for O O
amiodarone B-drug B-drug
concentration O O
using O O
RP-HPLC O O
. O O

The O O
geometric O O
mean O O
ratio O O
for O O
C O O
( O O
max O O
) O O
and O O
AUC O O
( O O
0-96 O O
) O O
was O O
calculated O O
. O O

There O O
were O O
no O O
significant O O
differences O O
between O O
the O O
pharmacokinetics O O
parameters O O
of O O
amiodarone B-drug B-drug
administered O O
intravenously O O
or O O
intragastrically O O
and O O
the O O
control O O
( O O
without O O
neferine B-drug_n O
) O O
group O O
( O O
with O O
ratios O O
of O O
0.7-1.4 O O
in O O
all O O
experimental O O
groups O O
) O O
, O O
suggesting O O
that O O
neferine B-drug_n B-drug
had O O
no O O
effect O O
on O O
amiodarone B-drug B-drug
plasma O O
pharmacokinetics O O
. O O

The O O
dosage O O
regimen O O
of O O
amiodarone B-drug B-drug
does O O
not O O
need O O
to O O
be O O
taken O O
into O O
consideration O O
when O O
combined O O
with O O
neferine B-drug_n B-drug
. O O

Structural O O
basis O O
for O O
alcohol B-drug B-drug
modulation O O
of O O
a O O
pentameric O B-group
ligand-gated O I-group
ion O I-group
channel O I-group
. O O

Despite O O
its O O
long O O
history O O
of O O
use O O
and O O
abuse O O
in O O
human O O
culture O O
, O O
the O O
molecular O O
basis O O
for O O
alcohol B-drug B-drug
action O O
in O O
the O O
brain O O
is O O
poorly O O
understood O O
. O O

The O O
recent O O
determination O O
of O O
the O O
atomic-scale O O
structure O O
of O O
GLIC O B-drug_n
, O O
a O O
prokaryotic O O
member O O
of O O
the O O
pentameric O O
ligand-gated O O
ion O O
channel O O
( O O
pLGIC O O
) O O
family O O
, O O
provides O O
a O O
unique O O
opportunity O O
to O O
characterize O O
the O O
structural O O
basis O O
for O O
modulation O O
of O O
these O O
channels O O
, O O
many O O
of O O
which O O
are O O
alcohol B-drug B-drug
targets O O
in O O
brain O O
. O O

We O O
observed O O
that O O
GLIC O O
recapitulates O O
bimodal O O
modulation O O
by O O
n-alcohols O B-drug_n
, O O
similar O O
to O O
some O O
eukaryotic O O
pLGICs O O
: O O
methanol B-drug_n B-drug
and O O
ethanol B-drug B-drug
weakly O O
potentiated O O
proton-activated O O
currents O O
in O O
GLIC O B-drug_n
, O O
whereas O O
n-alcohols O O
larger O O
than O O
ethanol O B-drug
inhibited O O
them O O
. O O

Mapping O O
of O O
residues O O
important O O
to O O
alcohol B-drug B-drug
modulation O O
of O O
ionotropic O O
receptors O O
for O O
glycine O B-drug
, O O
-aminobutyric O O
acid O O
, O O
and O O
acetylcholine O B-drug
onto O O
GLIC O O
revealed O O
their O O
proximity O O
to O O
transmembrane O O
cavities O O
that O O
may O O
accommodate O O
one O O
or O O
more O O
alcohol B-drug B-drug
molecules O O
. O O

Site-directed O O
mutations O O
in O O
the O O
pore-lining O O
M2 O O
helix O O
allowed O O
the O O
identification O O
of O O
four O O
residues O O
that O O
influence O O
alcohol B-drug B-drug
potentiation O O
, O O
with O O
the O O
direction O O
of O O
their O O
effects O O
reflecting O O
-helical O O
structure O O
. O O

At O O
one O O
of O O
the O O
potentiation-enhancing O O
residues O O
, O O
decreased O O
side O O
chain O O
volume O O
converted O O
GLIC O O
into O O
a O O
highly O O
ethanol-sensitive B-drug O
channel O O
, O O
comparable O O
to O O
its O O
eukaryotic O O
relatives O O
. O O

Covalent O O
labeling O O
of O O
M2 O O
positions O O
with O O
an O O
alcohol B-drug B-drug
analog O O
, O O
a O O
methanethiosulfonate O O
reagent O O
, O O
further O O
implicated O O
residues O O
at O O
the O O
extracellular O O
end O O
of O O
the O O
helix O O
in O O
alcohol O B-drug
binding O O
. O O

Molecular O O
dynamics O O
simulations O O
elucidated O O
the O O
structural O O
consequences O O
of O O
a O O
potentiation-enhancing O O
mutation O O
and O O
suggested O O
a O O
structural O O
mechanism O O
for O O
alcohol B-drug B-drug
potentiation O O
via O O
interaction O O
with O O
a O O
transmembrane O O
cavity O O
previously O O
termed O O
the O O
" O O
linking O O
tunnel O O
. O O
" O O

These O O
results O O
provide O O
a O O
unique O O
structural O O
model O O
for O O
independent O O
potentiating O O
and O O
inhibitory O O
interactions O O
of O O
n-alcohols O B-drug_n
with O O
a O O
pLGIC O O
family O O
member O O
. O O

Neuropharmacological O O
approach O O
against O O
MPTP B-drug_n B-drug_n
( O O
1-methyl-4-phenyl-1,2,3,6- B-drug_n O
tetrahydropyridine I-drug_n B-drug
) O O
-induced O O
mouse O O
model O O
of O O
Parkinson O O
's O O
disease O O
. O O

Parkinson O O
's O O
disease O O
( O O
PD O O
) O O
is O O
a O O
common O O
neurodegenerative O O
disease O O
that O O
appears O O
essentially O O
as O O
a O O
sporadic O O
condition O O
. O O

PD O O
is O O
well O O
known O O
to O O
be O O
a O O
chronic O O
and O O
progressive O O
neurodegenerative O O
disease O O
produced O O
by O O
a O O
selective O O
degeneration O O
of O O
dopaminergic O O
neurons O O
in O O
the O O
substantia O O
nigra O O
pars O O
compacta O O
. O O

The O O
main O O
clinical O O
features O O
of O O
PD O O
include O O
tremor O O
, O O
bradykinesia O O
, O O
rigidity O O
and O O
postural O O
instability O O
. O O

Most O O
insights O O
into O O
pathogenesis O O
of O O
PD O O
come O O
from O O
investigations O O
performed O O
in O O
experimental O O
models O O
of O O
PD O O
, O O
especially O O
those O O
produced O O
by O O
neurotoxins O B-group
. O O

The O O
biochemical O O
and O O
cellular O O
alterations O O
that O O
occur O O
after O O
1-methyl-4-phenyl-1,2,3,6- B-drug_n O
tetrahydropyridine I-drug_n B-drug_n
( O O
MPTP B-drug_n B-drug_n
) O O
treatment O O
are O O
remarkably O O
similar O O
to O O
that O O
observed O O
in O O
idiopathic O O
PD O O
. O O

Furthermore O O
, O O
it O O
is O O
well O O
known O O
that O O
acute O O
treatment O O
with O O
MPTP B-drug_n B-drug_n
can O O
cause O O
a O O
severe O O
loss O O
of O O
tyrosine O O
hydroxylase O O
and O O
dopamine O O
transporter O O
protein O O
levels O O
and O O
dopamine O O
contents O O
in O O
the O O
striatum O O
of O O
mice O O
, O O
as O O
compared O O
to O O
continuous O O
MPTP B-drug_n B-drug_n
treatment O O
. O O

Thus O O
these O O
findings O O
may O O
support O O
the O O
validity O O
of O O
acute O O
MPTP B-drug_n B-drug_n
treatment O O
model O O
for O O
unraveling O O
in O O
the O O
neurodegenerative O O
processes O O
in O O
PD O O
. O O

In O O
this O O
review O O
, O O
we O O
discuss O O
the O O
neuroprotective O O
effects O O
of O O
various O O
compounds O O
against O O
neuronal O O
cell O O
loss O O
in O O
an O O
MPTP B-drug_n B-drug_n
model O O
of O O
PD O O
. O O

This O O
review O O
may O O
lead O O
to O O
a O O
much O O
better O O
understanding O O
of O O
PD O O
as O O
well O O
as O O
provide O O
novel O O
clues O O
to O O
new O O
targets O O
for O O
therapeutic O O
interventions O O
in O O
PD O O
patients O O
. O O

Mechanisms O O
of O O
drug O O
toxicity O O
or O O
intolerance O O
. O O

Classically O O
, O O
adverse O O
drug O O
reactions O O
had O O
been O O
considered O O
as O O
type O O
A O O
reactions O O
which O O
are O O
related O O
to O O
the O O
main O O
pharmacological O O
action O O
of O O
the O O
drug O O
and O O
therefore O O
are O O
predictable O O
. O O

Such O O
reactions O O
are O O
predictable O O
, O O
reversible O O
, O O
and O O
usually O O
can O O
be O O
managed O O
by O O
lowering O O
the O O
dose O O
of O O
the O O
offending O O
drug O O
. O O

However O O
, O O
other O O
adverse O O
effects O O
of O O
drugs O O
can O O
occur O O
which O O
are O O
unrelated O O
to O O
the O O
main O O
pharmacological O O
action O O
of O O
the O O
drug O O
- O O
type O O
B O O
reactions O O
. O O

Such O O
adverse O O
effects O O
are O O
termed O O
idiosyncratic O O
and O O
are O O
often O O
initiated O O
by O O
metabolites O O
of O O
the O O
parent O O
drug O O
or O O
by O O
other O O
indirect O O
mechanisms O O
. O O

The O O
detailed O O
understanding O O
of O O
adverse O O
drug O O
events O O
has O O
become O O
a O O
major O O
focus O O
of O O
the O O
regulatory O O
agencies O O
throughout O O
the O O
world O O
. O O

The O O
pharmacotherapy O O
of O O
gastrointestinal O O
and O O
liver O O
disorders O O
is O O
becoming O O
increasingly O O
complex O O
. O O

In O O
recent O O
years O O
, O O
with O O
the O O
advent O O
of O O
novel O O
therapeutic O O
agents O O
to O O
treat O O
a O O
host O O
of O O
disorders O O
, O O
including O O
viral O O
hepatitis O O
, O O
gastrointestinal O O
motility O O
disorders O O
, O O
inflammatory O O
bowel O O
disease O O
and O O
others O O
, O O
the O O
potential O O
for O O
serious O O
clinically O O
relevant O O
drug O O
reactions O O
has O O
increased O O
. O O

In O O
the O O
pharmacotherapy O O
of O O
gastrointestinal O O
and O O
liver O O
diseases O O
, O O
a O O
significant O O
number O O
of O O
adverse O O
events O O
that O O
occur O O
can O O
be O O
explained O O
by O O
drug O O
interactions O O
. O O

Some O O
pharmacokinetic O O
drug O O
interactions O O
are O O
based O O
on O O
the O O
competitive O O
inhibition O O
of O O
the O O
rate O O
of O O
drug O O
metabolism O O
of O O
one O O
of O O
the O O
drugs O O
, O O
leading O O
to O O
an O O
increased O O
concentration O O
of O O
the O O
drug O O
which O O
was O O
not O O
intended O O
. O O

In O O
other O O
examples O O
, O O
the O O
interaction O O
can O O
be O O
mechanistic O O
in O O
which O O
one O O
or O O
more O O
drugs O O
when O O
co-administered O O
potentiate O O
each O O
other O O
's O O
actions O O
without O O
any O O
change O O
in O O
drug O O
levels O O
, O O
termed O O
pharmacodynamic O O
interactions O O
. O O

Unrecognized O O
fatalities O O
related O O
to O O
colchicine B-drug B-drug
in O O
hospitalized O O
patients O O
. O O

Colchicine B-drug B-drug
is O O
commonly O O
used O O
for O O
the O O
treatment O O
of O O
gout O O
and O O
occasionally O O
for O O
other O O
inflammatory O O
diseases O O
. O O

It O O
has O O
a O O
narrow O O
therapeutic O O
index O O
and O O
the O O
potential O O
for O O
severe O O
or O O
fatal O O
toxicity O O
. O O

We O O
sought O O
to O O
determine O O
( O O
1 O O
) O O
the O O
frequency O O
of O O
colchicine B-drug B-drug
toxicity O O
among O O
hospitalized O O
patients O O
taking O O
colchicine B-drug B-drug
who O O
died O O
during O O
an O O
admission O O
, O O
( O O
2 O O
) O O
the O O
likelihood O O
that O O
colchicine B-drug B-drug
contributed O O
to O O
death O O
, O O
( O O
3 O O
) O O
whether O O
patients O O
were O O
taking O O
interacting O O
medications O O
that O O
could O O
have O O
contributed O O
to O O
toxicity O O
, O O
and O O
( O O
4 O O
) O O
whether O O
colchicine B-drug B-drug
dosing O O
among O O
these O O
patients O O
adhered O O
to O O
established O O
guidelines O O
. O O

We O O
conducted O O
an O O
IRB-approved O O
, O O
retrospective O O
chart O O
review O O
at O O
an O O
urban O O
, O O
tertiary O O
care O O
, O O
1228-bed O O
, O O
university O O
hospital O O
. O O

Subjects O O
included O O
hospitalized O O
patients O O
who O O
received O O
colchicine B-drug B-drug
and O O
died O O
in O O
hospital O O
between O O
1 O O
January O O
2000 O O
and O O
28 O O
February O O
2007 O O
. O O

We O O
reviewed O O
charts O O
for O O
signs O O
and O O
symptoms O O
of O O
colchicine B-drug B-drug
toxicity O O
. O O

An O O
expert O O
panel O O
reviewed O O
each O O
case O O
and O O
classified O O
the O O
likelihood O O
of O O
colchicine B-drug B-drug
toxicity O O
, O O
the O O
likelihood O O
of O O
a O O
causal O O
role O O
of O O
colchicine B-drug B-drug
in O O
the O O
death O O
using O O
the O O
WHO O O
classification O O
system O O
, O O
and O O
the O O
appropriateness O O
of O O
colchicine B-drug B-drug
dosing O O
. O O

Thirty-seven O O
hospitalized O O
patients O O
who O O
died O O
during O O
the O O
86-month O O
study O O
period O O
received O O
colchicine B-drug B-drug
. O O

Toxicity O O
was O O
unlikely O O
in O O
20/37 O O
, O O
possible O O
in O O
8/37 O O
, O O
likely O O
in O O
5/37 O O
, O O
and O O
certain O O
in O O
4/37 O O
. O O

A O O
contributing O O
role O O
for O O
colchicine B-drug B-drug
in O O
causing O O
death O O
was O O
unlikely O O
in O O
24/37 O O
, O O
possible O O
in O O
7/37 O O
, O O
likely O O
in O O
3/37 O O
, O O
and O O
certain O O
in O O
3/37 O O
. O O

Colchicine B-drug B-drug
doses O O
( O O
based O O
on O O
creatinine O O
clearance O O
) O O
exceeded O O
the O O
accepted O O
range O O
for O O
12 O O
patients O O
, O O
including O O
10 O O
of O O
17 O O
cases O O
of O O
toxicity O O
and O O
8 O O
of O O
13 O O
cases O O
of O O
death O O
classified O O
as O O
possible O O
or O O
higher O O
. O O

Seventeen O O
patients O O
received O O
interacting O O
medications O O
, O O
including O O
8 O O
of O O
17 O O
cases O O
of O O
toxicity O O
and O O
8 O O
of O O
13 O O
cases O O
of O O
death O O
classified O O
as O O
possible O O
or O O
higher O O
. O O

Colchicine B-drug B-drug
toxicity O O
was O O
frequent O O
in O O
this O O
cohort O O
and O O
may O O
have O O
contributed O O
to O O
about O O
one-third O O
of O O
the O O
deaths O O
. O O

Inappropriate O O
dosing O O
of O O
colchicine B-drug B-drug
occurred O O
frequently O O
and O O
was O O
related O O
to O O
toxicity O O
and O O
death O O
. O O

Stroke O O
prevention O O
in O O
atrial O O
fibrillation O O
: O O
current O O
status O O
and O O
near-future O O
directions O O
. O O

Prevention O O
of O O
atrial O O
fibrillation-related O O
stroke O O
is O O
an O O
important O O
part O O
of O O
atrial O O
fibrillation O O
management O O
. O O

However O O
, O O
stroke O O
risk O O
is O O
not O O
homogeneous O O
and O O
varies O O
with O O
associated O O
morbidities O O
and O O
risk O O
factors O O
. O O

Risk O O
stratification O O
schemes O O
have O O
been O O
developed O O
that O O
categorize O O
patients O O
' O O
stroke O O
risk O O
into O O
classes O O
based O O
on O O
a O O
combination O O
of O O
risk O O
factors O O
. O O

According O O
to O O
the O O
calculated O O
level O O
of O O
risk O O
, O O
guidelines O O
recommend O O
patients O O
with O O
atrial O O
fibrillation O O
receive O O
antithrombotic B-group O
therapy O O
either O O
as O O
a O O
vitamin B-group B-group
K I-group I-group
antagonist I-group I-group
or O O
aspirin B-brand B-brand
. O O

Despite O O
recommendations O O
, O O
however O O
, O O
many O O
patients O O
with O O
atrial O O
fibrillation O O
do O O
not O O
receive O O
adequate O O
thromboprophylaxis O O
. O O

We O O
will O O
discuss O O
some O O
of O O
the O O
underlying O O
reasons O O
, O O
in O O
part O O
related O O
to O O
the O O
drawbacks O O
associated O O
with O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
. O O

These O O
highlight O O
the O O
need O O
for O O
new O O
anticoagulants B-group B-group
in O O
atrial O O
fibrillation O O
. O O

The O O
novel O O
oral O O
anticoagulants B-group B-group
in O O
development O O
may O O
overcome O O
some O O
of O O
the O O
limitations O O
of O O
vitamin B-group B-group
K I-group I-group
antagonists I-group I-group
and O O
address O O
their O O
underuse O O
and O O
safety O O
concerns O O
. O O

Combining O O
chondroitinase O O
ABC O O
and O O
growth O O
factors O O
promotes O O
the O O
integration O O
of O O
murine O O
retinal O O
progenitor O O
cells O O
transplanted O O
into O O
Rho O O
( O O
-/- O O
) O O
mice O O
. O O

The O O
aim O O
of O O
this O O
study O O
is O O
to O O
investigate O O
the O O
synergistic O O
effect O O
of O O
chondroitinase O O
ABC O O
and O O
growth O O
factors O O
in O O
the O O
integration O O
of O O
murine O O
retinal O O
progenitor O O
cells O O
( O O
mRPCs O O
) O O
transplanted O O
into O O
Rho O O
( O O
-/- O O
) O O
mice O O
. O O

mRPCs O O
from O O
P1 O O
green O O
fluorescent O O
protein-transgenic O O
mice O O
were O O
isolated O O
and O O
expanded O O
for O O
transplantation O O
. O O

All O O
mRPCs O O
of O O
20 O O
passages O O
or O O
less O O
were O O
transplanted O O
into O O
the O O
subretinal O O
space O O
of O O
B6 O O
mice O O
together O O
with O O
chondroitinase O O
ABC O O
, O O
and O O
into O O
Rho O O
( O O
-/- O O
) O O
mice O O
combined O O
with O O
chondroitinase O O
ABC O O
, O O
N- B-drug_n O
[ I-drug_n O
N- I-drug_n O
( I-drug_n O
3 I-drug_n O
, I-drug_n O
5-Difluorophenacetyl I-drug_n B-drug_n
) I-drug_n I-drug_n
-L-alanyl I-drug_n I-drug_n
] I-drug_n O
-S-phenylglycine I-drug_n O
t-butyl I-drug_n O
ester I-drug_n O
( O O
DAPT B-drug_n O
) O O
, O O
and O O
insulin B-drug_n B-drug
growth I-drug_n O
factor I-drug_n O
( I-drug_n O
IGF I-drug_n O
) I-drug_n O
-1 I-drug_n O
. O O

Cell O O
counts O O
were O O
used O O
to O O
examine O O
the O O
migration O O
and O O
survival O O
rate O O
of O O
mRPCs O O
in O O
B6 O O
mice O O
. O O

Immunohistochemistry O O
was O O
used O O
to O O
evaluate O O
the O O
differentiation O O
and O O
integration O O
of O O
mRPCs O O
in O O
B6 O O
and O O
Rho O O
( O O
-/- O O
) O O
mice O O
. O O

Our O O
results O O
show O O
that O O
substantial O O
numbers O O
of O O
mRPCs O O
migrated O O
and O O
survived O O
in O O
the O O
retina O O
when O O
transplanted O O
with O O
chondroitinase O O
ABC O O
into O O
B6 O O
and O O
Rho O O
( O O
-/- O O
) O O
mice O O
. O O

Chondroitinase O O
ABC O O
disrupted O O
the O O
glial O O
scar O O
around O O
the O O
mRPCs O O
in O O
the O O
subretinal O O
space O O
. O O

Only O O
a O O
few O O
mRPCs O O
expressed O O
recoverin O O
in O O
B6 O O
mice O O
. O O

More O O
mRPCs O O
expressed O O
rhodopsin O O
, O O
recoverin O B-drug
, O O
and O O
synaptophysin O O
after O O
transplantation O O
into O O
Rho O O
( O O
-/- O O
) O O
mice O O
when O O
combined O O
with O O
chondroitinase O O
ABC O O
and O O
growth O O
factors O O
. O O

The O O
synergistic O O
effect O O
of O O
chondroitinase O O
ABC O O
and O O
growth O O
factors O O
facilitates O O
the O O
anatomic O O
integration O O
of O O
mRPCs O O
transplanted O O
into O O
Rho O O
( O O
-/- O O
) O O
mice O O
. O O

Placebo O O
effect O O
in O O
patients O O
with O O
irritable O O
bowel O O
syndrome O O
. O O

The O O
placebo O O
effect O O
has O O
evolved O O
from O O
being O O
considered O O
a O O
nuisance O O
factor O O
in O O
clinical O O
research O O
to O O
a O O
hot O O
topic O O
of O O
scientific O O
investigation O O
. O O

New O O
research O O
findings O O
show O O
that O O
a O O
placebo O O
has O O
real O O
psychobiological O O
and O O
biological O O
effects O O
that O O
are O O
attributable O O
to O O
the O O
overall O O
therapeutic O O
context O O
. O O

Irritable O O
bowel O O
syndrome O O
( O O
IBS O O
) O O
is O O
a O O
functional O O
disorder O O
of O O
the O O
gastrointestinal O O
tract O O
that O O
shows O O
a O O
significant O O
placebo O O
response O O
of O O
around O O
40 O O
50 O O
% O O
among O O
different O O
clinical O O
trials.A O O
positive O O
patient-practitioner O O
relationship O O
can O O
enhance O O
the O O
placebo O O
effect O O
in O O
IBS O O
patients O O
. O O

Emerging O O
literature O O
using O O
functional O O
brain O O
imaging O O
has O O
started O O
to O O
document O O
the O O
neuronal O O
changes O O
associated O O
with O O
the O O
placebo O O
phenomenon O O
in O O
IBS O O
patients O O
, O O
showing O O
aberrant O O
neural O O
network O O
during O O
visceral O O
placebo O O
analgesia O O
when O O
compared O O
to O O
controls O O
. O O

Further O O
promotion O O
and O O
integration O O
of O O
laboratory O O
and O O
clinical O O
research O O
are O O
encouraged O O
to O O
advance O O
the O O
understanding O O
of O O
placebo O O
mechanisms O O
in O O
IBS O O
patients O O
. O O

[ O O
Seniors O O
and O O
cardiovascular O O
medications O O
] O O
. O O

Authors O O
analyze O O
the O O
situation O O
in O O
the O O
therapy O O
of O O
cardiovascular O O
diseases O O
-- O O
unsatisfactory O O
situation O O
especially O O
from O O
the O O
dyslipidaemia O O
point O O
of O O
view O O
. O O

Different O O
groups O O
of O O
medications O O
are O O
discussed O O
and O O
their O O
risks O O
for O O
elderly O O
patients O O
. O O

Angiotensin B-group B-group
converting I-group I-group
enzyme I-group I-group
blockers I-group I-group
and O O
their O O
influence O O
on O O
the O O
endothelial O O
dysfunction O O
, O O
but O O
the O O
risk O O
of O O
hyperpotassemia O O
are O O
showed O O
. O O

The O O
risk O O
of O O
gastrointestinal O O
bleeding O O
during O O
the O O
treatment O O
with O O
antiagregants B-group B-group
and O O
anticoagulants B-group B-group
, O O
the O O
risk O O
of O O
bradycardia O O
in O O
beta-blockade O O
, O O
possible O O
interactions O O
with O O
other O O
medications O O
lowering O O
the O O
heart O O
rate O O
are O O
discussed O O
. O O

Attention O O
is O O
paid O O
to O O
calcium B-group B-group
channel I-group I-group
blockers I-group I-group
, O O
diuretics B-group B-group
and O O
digoxin B-drug B-drug
. O O

The O O
table O O
containing O O
possible O O
clinical O O
symptoms O O
of O O
unwanted O O
side O O
effect O O
of O O
most O O
frequently O O
used O O
cardiovascular O O
medications O O
in O O
elderly O O
is O O
added O O
as O O
the O O
conclusion O O
of O O
the O O
article O O
. O O

Post-exposure O O
prophylaxis O O
for O O
H1N1 O O
with O O
oseltamivir B-drug B-drug
in O O
renal O O
allograft O O
recipient O O
-- O O
safe O O
and O O
effective O O
without O O
any O O
immunosuppresive B-group O
drug I-group O
interaction O O
. O O

Kidney O O
transplant O O
recipients O O
are O O
at O O
a O O
high O O
risk O O
for O O
H1N1 O O
infection O O
associated O O
complications O O
during O O
the O O
current O O
pandemic O O
. O O

Prevention O O
of O O
infection O O
by O O
immunization O O
, O O
together O O
with O O
early O O
recognition O O
and O O
prompt O O
antiviral O O
treatment O O
are O O
critical O O
. O O

Post-exposure O O
prophylaxis O O
of O O
H1N1 O O
with O O
oseltamivir B-drug B-drug
was O O
safe O O
, O O
effective O O
and O O
well O O
tolerated O O
to O O
prevent O O
H1N1 O O
influenza O O
A O O
virus O O
infection O O
in O O
newly O O
transplanted O O
renal O O
allograft O O
recipient O O
receiving O O
triple O O
immunosuppression O O
without O O
any O O
interaction O O
with O O
tacrolimus B-drug B-drug
level O O
. O O

Oseltamivir B-drug B-drug
was O O
effective O O
for O O
post-exposure O O
prophylaxis O O
of O O
H1N1 O O
in O O
close O O
contact O O
. O O

Clarity O O
and O O
applicability O O
of O O
drug-drug O O
interaction O O
management O O
guidelines O O
: O O
a O O
systematic O O
appraisal O O
by O O
general O O
practitioners O O
and O O
community O O
pharmacists O O
in O O
the O O
Netherlands O O
. O O

Despite O O
the O O
availability O O
and O O
daily O O
use O O
of O O
computerized O O
drug-drug O O
interaction O O
surveillance O O
systems O O
, O O
exposure O O
to O O
potentially O O
relevant O O
drug-drug O O
interactions O O
( O O
DDIs O O
) O O
continues O O
. O O

DDI O O
management O O
guidelines O O
are O O
often O O
inadequate O O
and O O
clear O O
management O O
options O O
are O O
lacking O O
, O O
which O O
attributes O O
to O O
overriding O O
of O O
DDI O O
signals O O
. O O

Although O O
general O O
criteria O O
for O O
the O O
development O O
and O O
reporting O O
of O O
high-quality O O
clinical O O
practice O O
guidelines O O
have O O
been O O
identified O O
, O O
it O O
appears O O
these O O
have O O
not O O
yet O O
been O O
applied O O
to O O
DDI O O
management O O
guidelines O O
. O O

The O O
aim O O
of O O
the O O
study O O
was O O
to O O
assess O O
the O O
clarity O O
and O O
applicability O O
of O O
guidelines O O
for O O
the O O
management O O
of O O
potentially O O
harmful O O
DDIs O O
. O O

We O O
selected O O
13 O O
DDIs O O
that O O
are O O
potentially O O
harmful O O
for O O
patients O O
and O O
frequently O O
occur O O
in O O
community O O
pharmacy O O
practice O O
in O O
the O O
Netherlands O O
. O O

The O O
clarity O O
and O O
applicability O O
of O O
the O O
management O O
guidelines O O
of O O
these O O
DDIs O O
were O O
appraised O O
using O O
the O O
appropriate O O
two O O
domains O O
- O O
'Clarity O O
and O O
presentation O O
' O O
and O O
'Applicability O O
' O O
, O O
of O O
the O O
validated O O
Appraisal O O
of O O
Guidelines O O
for O O
Research O O
and O O
Evaluation O O
( O O
AGREE O O
) O O
Instrument O O
. O O

The O O
appraisal O O
was O O
performed O O
by O O
12 O O
community O O
pharmacists O O
and O O
12 O O
general O O
practitioners O O
. O O

The O O
standardized O O
domain O O
scores O O
and O O
mean O O
item O O
scores O O
for O O
'Clarity O O
and O O
presentation O O
' O O
and O O
'Applicability O O
' O O
were O O
compared O O
. O O

All O O
DDI O B-drug
management O O
guidelines O O
were O O
generally O O
found O O
to O O
score O O
well O O
on O O
'Clarity O O
and O O
presentation O O
' O O
, O O
but O O
poorly O O
with O O
respect O O
to O O
'Applicability O O
' O O
( O O
standardized O O
domain O O
scores O O
68.0 O O
vs O O
26.1 O O
% O O
) O O
. O O

Within O O
the O O
domain O O
'Clarity O O
and O O
presentation O O
' O O
, O O
the O O
item O O
'tools O B-drug
for O O
application O O
' O O
received O O
the O O
lowest O O
scores O O
. O O

Within O O
the O O
domain O O
'Applicability O O
' O O
, O O
cost O O
implications O O
, O O
organizational O O
barriers O O
and O O
key O O
review O O
criteria O O
were O O
all O O
poorly O O
documented O O
. O O

All O O
guidelines O O
presented O O
non-directive O O
advice O O
using O O
words O O
such O O
as O O
'consider O O
' O O
and O O
'regularly O O
' O O
. O O

Developers O O
of O O
DDI O B-drug
management O O
guidelines O O
should O O
take O O
the O O
appropriate O O
domains O O
of O O
the O O
AGREE O O
Instrument O O
into O O
consideration O O
in O O
their O O
development O O
processes O O
. O O

The O O
applicability O O
of O O
DDI O B-drug
management O O
guidelines O O
should O O
be O O
pretested O O
before O O
publishing O O
. O O

To O O
improve O O
guideline O O
quality O O
, O O
more O O
attention O O
should O O
particularly O O
be O O
paid O O
to O O
the O O
available O O
tools O O
for O O
applications O O
and O O
cost O O
implications O O
. O O

Motor O O
deficits O O
and O O
recovery O O
in O O
rats O O
with O O
unilateral O O
spinal O O
cord O O
hemisection O O
mimic O O
the O O
Brown-Sequard O O
syndrome O O
. O O

Cervical O O
incomplete O O
spinal O O
cord O O
injuries O O
often O O
lead O O
to O O
severe O O
and O O
persistent O O
impairments O O
of O O
sensorimotor O O
functions O O
and O O
are O O
clinically O O
the O O
most O O
frequent O O
type O O
of O O
spinal O O
cord O O
injury O O
. O O

Understanding O O
the O O
motor O O
impairments O O
and O O
the O O
possible O O
functional O O
recovery O O
of O O
upper O O
and O O
lower O O
extremities O O
is O O
of O O
great O O
importance O O
. O O

Animal O O
models O O
investigating O O
motor O O
dysfunction O O
following O O
cervical O O
spinal O O
cord O O
injury O O
are O O
rare O O
. O O

We O O
analysed O O
the O O
differential O O
spontaneous O O
recovery O O
of O O
fore- O O
and O O
hindlimb O O
locomotion O O
by O O
detailed O O
kinematic O O
analysis O O
in O O
adult O O
rats O O
with O O
unilateral O O
C4/C5 O O
hemisection O O
, O O
a O O
lesion O O
that O O
leads O O
to O O
the O O
Brown-S O O
quard O O
syndrome O O
in O O
humans O O
. O O

The O O
results O O
showed O O
disproportionately O O
better O O
performance O O
of O O
hindlimb O O
compared O O
with O O
forelimb O O
locomotion O O
; O O

hindlimb O O
locomotion O O
showed O O
substantial O O
recovery O O
, O O
whereas O O
the O O
ipsilesional O O
forelimb O O
remained O O
in O O
a O O
very O O
poor O O
functional O O
state O O
. O O

Such O O
a O O
differential O O
motor O O
recovery O O
pattern O O
is O O
also O O
known O O
to O O
occur O O
in O O
monkeys O O
and O O
in O O
humans O O
after O O
similar O O
spinal O O
cord O O
lesions O O
. O O

On O O
the O O
lesioned O O
side O O
, O O
cortico- O O
, O O
rubro- O O
, O O
vestibulo- O O
and O O
reticulospinal O O
tracts O O
and O O
the O O
important O O
modulatory O O
serotonergic O O
, O O
dopaminergic O O
and O O
noradrenergic O O
fibre O O
systems O O
were O O
interrupted O O
by O O
the O O
lesion O O
. O O

In O O
an O O
attempt O O
to O O
facilitate O O
locomotion O O
, O O
different O O
monoaminergic O B-group
agonists O I-group
were O O
injected O O
intrathecally O O
. O O

Injections O O
of O O
specific O O
serotonergic O O
and O O
noradrenergic O O
agonists O O
in O O
the O O
chronic O O
phase O O
after O O
the O O
spinal O O
cord O O
lesion O O
revealed O O
remarkable O O
, O O
although O O
mostly O O
functionally O O
negative O O
, O O
modulations O O
of O O
particular O O
parameters O O
of O O
hindlimb O O
locomotion O O
. O O

In O O
contrast O O
, O O
forelimb O O
locomotion O O
was O O
mostly O O
unresponsive O O
to O O
these O O
agonists O O
. O O

These O O
results O O
, O O
therefore O O
, O O
show O O
fundamental O O
differences O O
between O O
fore- O O
and O O
hindlimb O O
spinal O O
motor O O
circuitries O O
and O O
their O O
functional O O
dependence O O
on O O
remaining O O
descending O O
inputs O O
and O O
exogenous O O
spinal O O
excitation O O
. O O

Understanding O O
these O O
differences O O
may O O
help O O
to O O
develop O O
future O O
therapeutic O O
strategies O O
to O O
improve O O
upper O O
and O O
lower O O
limb O O
function O O
in O O
patients O O
with O O
incomplete O O
cervical O O
spinal O O
cord O O
injuries O O
. O O

Improvement O O
of O O
colchicine B-drug B-drug
oral O O
bioavailability O O
by O O
incorporating O O
eugenol B-drug B-drug
in O O
the O O
nanoemulsion O O
as O O
an O O
oil O O
excipient O O
and O O
enhancer O O
. O O

The O O
effect O O
of O O
eugenol B-drug B-drug
on O O
colchicine B-drug B-drug
transport O O
across O O
an O O
isolated O O
rat O O
intestinal O O
membrane O O
was O O
studied O O
using O O
an O O
in O O
vitro O O
diffusion O O
chamber O O
system O O
. O O

We O O
found O O
that O O
eugenol B-drug B-drug
increased O O
the O O
absorptive O O
transport O O
of O O
the O O
drug O O
efficiently O O
. O O

The O O
effect O O
of O O
eugenol B-drug B-drug
on O O
intestinal O O
absorption O O
of O O
colchicine B-drug B-drug
in O O
an O O
oral O O
administrative O O
nanoemulsion O O
formulation O O
was O O
also O O
demonstrated O O
in O O
vivo O O
. O O

The O O
colchicine B-drug B-drug
nanoemulsion O O
was O O
prepared O O
with O O
isopropyl B-drug_n B-drug
myristate I-drug_n I-drug
, O O
eugenol B-drug B-drug
, O O
Tween80 B-drug_n O
, O O
ethanol B-drug B-drug
and O O
water O O
, O O
and O O
eugenol B-drug B-drug
was O O
used O O
as O O
an O O
oil O O
phase O O
in O O
the O O
formulation O O
; O O

an O O
average O O
particle O O
size O O
of O O
this O O
nanoemulsion O O
was O O
41.2 O O
7.2 O O
nm O O
. O O

The O O
permeation O O
of O O
colchicine B-drug B-drug
in O O
the O O
nanoemulsion O O
across O O
the O O
intestinal O O
membrane O O
was O O
significantly O O
different O O
from O O
that O O
of O O
the O O
control O O
group O O
( O O
0.2 O O
mM O O
colchicine B-drug B-drug
) O O
. O O

Finally O O
, O O
co-administration O O
of O O
eugenol B-drug B-drug
in O O
colchicine B-drug B-drug
nanoemulsion O O
to O O
enhance O O
the O O
colchicine B-drug B-drug
bioavailability O O
was O O
investigated O O
by O O
an O O
oral O O
administration O O
method O O
. O O

After O O
oral O O
administration O O
of O O
colchicine B-drug B-drug
( O O
8 O O
mg/kg O O
) O O
in O O
the O O
form O O
of O O
either O O
the O O
nanoemulsion O O
or O O
in O O
free O O
colchicine B-drug B-drug
solution O O
, O O
the O O
relative O O
bioavailability O O
of O O
nanoemulsion O O
and O O
eugenol-nanoemulsion B-drug O
were O O
enhanced O O
by O O
about O O
1.6- O O
and O O
2.1-fold O O
, O O
respectively O O
, O O
compared O O
with O O
free O O
colchicine B-drug B-drug
solution O O
. O O

The O O
procedure O O
indicated O O
that O O
the O O
intestinal O O
absorption O O
of O O
colchicine B-drug B-drug
was O O
enhanced O O
significantly O O
by O O
eugenol B-drug B-drug
in O O
the O O
tested O O
nanoemulsion O O
. O O

All O O
the O O
results O O
suggested O O
that O O
eugenol B-drug B-drug
is O O
an O O
efficient O O
component O O
in O O
an O O
oral O O
administrative O O
formulation O O
for O O
improving O O
the O O
intestinal O O
absorption O O
of O O
colchicine B-drug B-drug
. O O

[ O O
Protective O O
effects O O
of O O
ginseng-ginko B-drug B-drug_n
extracts O O
combination O O
on O O
rat O O
primary O O
cultured O O
neurons O O
induced O O
by O O
Abeta B-drug_n B-drug_n
( I-drug_n O
1-40 I-drug_n O
) I-drug_n O
] O O
. O O

To O O
observe O O
the O O
injury O O
in O O
rat O O
primary O O
cultured O O
neurons O O
induced O O
by O O
Abeta B-drug_n B-drug_n
( I-drug_n O
1-40 I-drug_n O
) I-drug_n O
and O O
the O O
protective O O
effects O O
of O O
combination O O
of O O
ginseng B-drug B-drug_n
and O O
ginko B-drug O
extracts O O
. O O

Primary O O
neurons O O
were O O
induced O O
by O O
Abeta B-drug_n B-drug_n
( I-drug_n O
1-40 I-drug_n O
) I-drug_n O
to O O
establish O O
the O O
cell O O
model O O
of O O
toxic O O
injury O O
. O O

Using O O
flow O O
cytometry O O
with O O
Annexin O B-drug_n
V-FITC/PI O O
double O O
staining O O
, O O
MTP O O
assay O O
, O O
transmission O O
electron O O
microscopy O O
and O O
Western O O
blot O O
, O O
the O O
appropriate O O
concentration O O
and O O
duration O O
of O O
AP O O
for O O
cell O O
model O O
establishment O O
were O O
determined O O
. O O

The O O
effects O O
of O O
extracts O O
of O O
ginseng B-drug B-drug_n
and O O
ginko B-drug B-drug_n
( O O
EGGB B-drug O
) O O
on O O
cellular O O
proliferative O O
activity O O
, O O
apoptotic O O
rate O O
, O O
ultrastructure O O
and O O
caspase-3 O O
expression O O
were O O
detected O O
. O O

The O O
apoptotic O O
rate O O
was O O
increased O O
significantly O O
after O O
neurons O O
were O O
induced O O
by O O
1 O O
micromol O O
x O O
L O O
( O O
-1 O O
) O O
Abeta B-drug_n B-brand
( I-drug_n O
-40 I-drug_n O
) I-drug_n O
for O O
24 O O
h O O
( O O
P O O
< O O
0.01 O O
) O O
. O O

EGGB B-drug O
( O O
5 O O
, O O
50 O O
mg O O
L O O
( O O
-1 O O
) O O
) O O
significantly O O
enhanced O O
the O O
proliferative O O
activity O O
( O O
P O O
< O O
0.05 O O
) O O
. O O

Meanwhile O O
, O O
EGGB B-drug O
( O O
50 O O
mg O O
L O O
( O O
-1 O O
) O O
) O O
inhibited O O
neuronal O O
apoptosis O O
and O O
caspase-3 O O
overexpression O O
and O O
improved O O
cellular O O
ultrastructure O O
remarkably O O
( O O
P O O
< O O
0.05 O O
, O O
P O O
< O O
0.01 O O
) O O
. O O

Abeta B-drug B-drug_n
( I-drug O
1-40 I-drug O
) I-drug O
could O O
significantly O O
induce O O
primary O O
cultured O O
neurons O O
to O O
apoptosis O O
in O O
vitro O O
. O O

EGGB B-drug O
showed O O
beneficial O O
neuroprotective O O
effects O O
against O O
neuronal O O
apoptosis O O
, O O
which O O
might O O
be O O
due O O
to O O
improving O O
the O O
structures O O
of O O
neuron O O
and O O
its O O
subcellular O O
organelles O O
, O O
enhancing O O
cellular O O
proliferative O O
activity O O
and O O
inhibiting O O
caspase-3 O O
overexpression O O
in O O
neurons O O
. O O

[ O O
Effects O O
of O O
glycyrrhiza B-drug_n B-drug_n
extract I-drug_n I-drug_n
on O O
pharmacokinetics O O
property O O
of O O
daphnetin B-drug_n B-drug
in O O
rats O O
] O O
. O O

To O O
research O O
the O O
influence O O
of O O
glycyrrhiza B-drug_n B-drug_n
extract I-drug_n I-drug_n
on O O
the O O
pharmacokinetics O O
characteristic O O
parameters O O
of O O
daphnetin B-drug_n B-drug
, O O
which O O
was O O
aimed O O
to O O
explore O O
the O O
rationality O O
of O O
concert O O
application O O
of O O
drugs O O
. O O

The O O
rats O O
received O O
intragastric O O
administration O O
of O O
daphnetin B-drug_n B-drug
and O O
glycyrrhiza B-drug_n O
extract I-drug_n O
containing O O
the O O
same O O
daphnetin B-drug_n B-drug
respectively O O
. O O

The O O
blood O O
concentration O O
of O O
daphnetin B-drug_n B-drug
was O O
assayed O O
by O O
LC-MS O O
. O O

The O O
data O O
was O O
processed O O
by O O
program O O
DAS2.1.1 O O
. O O

Glycyrrhiza O O
extract O O
can O O
reduce O O
the O O
t O O
( O O
1/2 O O
) O O
, O O
tmax O O
and O O
Ke O O
of O O
daphnetin B-drug_n B-drug
, O O
while O O
increased O O
the O O
Ka O O
and O O
AUC O O
( O O
0-infinity O O
) O O
. O O

Glycyrrhiza O O
extract O O
promoted O O
the O O
oral O O
absorption O O
of O O
daphnetin B-drug_n B-drug
, O O
slowed O O
down O O
the O O
elimination O O
and O O
increased O O
the O O
biological O O
availability O O
. O O

Antimicrobial O O
effects O O
of O O
o-cymen-5-ol B-drug_n O
and O O
zinc B-drug B-drug
, O O
alone O O
& O O

in O O
combination O O
in O O
simple O O
solutions O O
and O O
toothpaste O O
formulations O O
. O O

This O O
study O O
aimed O O
to O O
evaluate O O
antimicrobial O O
effects O O
of O O
an O O
o-cymen-5-ol/zinc B-drug_n O
system O O
. O O

o-Cymen-5-ol B-drug_n O
and O O
zinc B-drug B-drug
gluconate I-drug I-drug
minimum O O
inhibitory O O
concentration O O
( O O
MIC O O
) O O
and O O
minimum O O
bactericidal O O
concentration O O
( O O
MBC O O
) O O
were O O
determined O O
against O O
Streptococcus O O
mutans O O
, O O
Actinomyces O O
viscosus O O
, O O
Porphyromonas O O
gingivalis O O
, O O
Fusobacterium O O
nucleatum O O
and O O
Candida O O
albicans O O
. O O

Synergy O O
was O O
investigated O O
by O O
checkerboard O O
MIC/MBC O O
; O O

inhibition O O
of O O
P O O
. O O

gingivalis O B-group
protease O I-group
activity O O
and O O
S O O
. O O

mutans O O
glycolysis O O
were O O
investigated O O
. O O

Slurried O O
toothpastes O O
containing O O
the O O
system O O
were O O
assessed O O
in O O
kill O O
time O O
assays O O
against O O
S O O
. O O

mutans O O
and O O
E O O
. O O

coli O O
. O O

o-Cymen-5-ol B-drug_n O
MIC O O
was O O
between O O
1.7 O O
mM O O
to O O
3.4 O O
mM O O
; O O

MBC O O
was O O
3.4 O O
mM O O
to O O
6.7 O O
mM O O
. O O

Zinc B-drug B-drug
gluconate I-drug I-drug
MIC O O
was O O
2.8 O O
mM O O
to O O
11 O O
mM O O
; O O

MBC O O
was O O
between O O
11 O O
mM O O
and O O
> O O
44 O O
mM O O
. O O

The O O
two O O
agents O O
in O O
solution O O
showed O O
synergy O O
( O O
FICI O O
0.50 O O
) O O
against O O
P O O
. O O

gingivalis O O
and O O
F O O
. O O

nucleatum O O
, O O
with O O
MIC O O
of O O
0.42 O O
mM/0.69 O O
mM O O
for O O
o-cymen-5-ol/zinc B-drug_n B-drug
gluconate B-drug I-drug
, O O
respectively O O
. O O

Zinc B-drug B-drug
inhibited O O
glycolysis O O
and O O
protease O O
to O O
a O O
greater O O
degree O O
than O O
o-cymen-5-ol B-drug_n O
; O O

glycolysis O O
inhibition O O
by O O
the O O
two O O
agents O O
was O O
additive O O
. O O

o-Cymen-5-ol/zinc B-drug_n B-drug
chloride B-drug I-drug
in O O
toothpaste O O
showed O O
greater O O
effects O O
than O O
placebo O O
( O O
120s O O
log10 O O
kill=7.35 O O
0.40 O O
and O O
4.02 O O
0.40 O O
, O O
respectively O O
) O O
. O O

The O O
zinc/o-cymen-5-ol B-drug B-drug
system O O
has O O
direct O O
antimicrobial O O
effects O O
and O O
inhibits O O
oral O O
disease-related O O
processes O O
. O O

Synergistic O O
effects O O
were O O
seen O O
against O O
anaerobes O O
. O O

A O O
system O O
combining O O
o-cymen-5-ol B-drug_n O
and O O
zinc B-drug B-drug
shows O O
properties O O
desirable O O
for O O
incorporation O O
in O O
toothpastes O O
. O O

Opportunities O O
and O O
challenges O O
in O O
the O O
development O O
of O O
experimental O O
drug O O
combinations O O
for O O
cancer O O
. O O

It O O
is O O
becoming O O
increasingly O O
evident O O
that O O
cancers O O
are O O
dependent O O
on O O
a O O
number O O
of O O
altered O O
molecular O O
pathways O O
and O O
can O O
develop O O
diverse O O
mechanisms O O
of O O
resistance O O
to O O
therapy O O
with O O
single O O
agents O O
. O O

Therefore O O
, O O
combination O O
regimens O O
may O O
provide O O
the O O
best O O
hope O O
for O O
effective O O
therapies O O
with O O
durable O O
effects O O
. O O

Despite O O
preclinical O O
data O O
to O O
support O O
this O O
notion O O
, O O
there O O
are O O
many O O
challenges O O
to O O
the O O
development O O
of O O
targeted O O
combinations O O
including O O
scientific O O
, O O
economic O O
, O O
legal O O
, O O
and O O
regulatory O O
barriers O O
. O O

A O O
discussion O O
of O O
these O O
challenges O O
and O O
identification O O
of O O
models O O
and O O
best O O
practices O O
are O O
presented O O
with O O
intent O O
of O O
aiding O O
the O O
research O O
community O O
in O O
addressing O O
real O O
and O O
perceived O O
barriers O O
to O O
the O O
development O O
of O O
combination O O
therapies O O
for O O
cancer O O
. O O

Network O O
neighbors O O
of O O
drug O O
targets O O
contribute O O
to O O
drug O O
side-effect O O
similarity O O
. O O

In O O
pharmacology O O
, O O
it O O
is O O
essential O O
to O O
identify O O
the O O
molecular O O
mechanisms O O
of O O
drug O O
action O O
in O O
order O O
to O O
understand O O
adverse O O
side O O
effects O O
. O O

These O O
adverse O O
side O O
effects O O
have O O
been O O
used O O
to O O
infer O O
whether O O
two O O
drugs O O
share O O
a O O
target O O
protein O O
. O O

However O O
, O O
side-effect O O
similarity O O
of O O
drugs O O
could O O
also O O
be O O
caused O O
by O O
their O O
target O O
proteins O O
being O O
close O O
in O O
a O O
molecular O O
network O O
, O O
which O O
as O O
such O O
could O O
cause O O
similar O O
downstream O O
effects O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
proportion O O
of O O
side-effect O O
similarities O O
that O O
is O O
due O O
to O O
targets O O
that O O
are O O
close O O
in O O
the O O
network O O
compared O O
to O O
shared O O
drug O O
targets O O
. O O

We O O
found O O
that O O
only O O
a O O
minor O O
fraction O O
of O O
side-effect O O
similarities O O
( O O
5.8 O O
% O O
) O O
are O O
caused O O
by O O
drugs O O
targeting O O
proteins O O
close O O
in O O
the O O
network O O
, O O
compared O O
to O O
side-effect O O
similarities O O
caused O O
by O O
overlapping O O
drug O O
targets O O
( O O
64 O O
% O O
) O O
. O O

Moreover O O
, O O
these O O
targets O O
that O O
cause O O
similar O O
side O O
effects O O
are O O
more O O
often O O
in O O
a O O
linear O O
part O O
of O O
the O O
network O O
, O O
having O O
two O O
or O O
less O O
interactions O O
, O O
than O O
drug O O
targets O O
in O O
general O O
. O O

Based O O
on O O
the O O
examples O O
, O O
we O O
gained O O
novel O O
insight O O
into O O
the O O
molecular O O
mechanisms O O
of O O
side O O
effects O O
associated O O
with O O
several O O
drug O O
targets O O
. O O

Looking O O
forward O O
, O O
such O O
analyses O O
will O O
be O O
extremely O O
useful O O
in O O
the O O
process O O
of O O
drug O O
development O O
to O O
better O O
understand O O
adverse O O
side O O
effects O O
. O O

[ O O
Does O O
implementation O O
of O O
benchmarking O O
in O O
quality O O
circles O O
improve O O
the O O
quality O O
of O O
care O O
of O O
patients O O
with O O
asthma O O
and O O
reduce O O
drug O O
interaction O O
] O O
. O O

The O O
purpose O O
of O O
this O O
cluster-randomised O O
controlled O O
trial O O
was O O
to O O
evaluate O O
the O O
efficacy O O
of O O
quality O O
circles O O
( O O
QCs O O
) O O
working O O
either O O
with O O
general O O
data-based O O
feedback O O
or O O
with O O
an O O
open O O
benchmark O O
within O O
the O O
field O O
of O O
asthma O O
care O O
and O O
drug-drug O O
interactions O O
. O O

Twelve O O
QCs O O
, O O
involving O O
96 O O
general O O
practitioners O O
from O O
85 O O
practices O O
, O O
were O O
randomised O O
. O O

Six O O
QCs O O
worked O O
with O O
traditional O O
anonymous O O
feedback O O
and O O
six O O
with O O
an O O
open O O
benchmark O O
. O O

Two O O
QC O O
meetings O O
supported O O
with O O
feedback O O
reports O O
were O O
held O O
covering O O
the O O
topics O O
" O O
drug-drug O O
interactions O O
" O O

and O O
" O O
asthma O O
" O O
; O O

in O O
both O O
cases O O
discussions O O
were O O
guided O O
by O O
a O O
trained O O
moderator O O
. O O

Outcome O O
measures O O
included O O
health-related O O
quality O O
of O O
life O O
and O O
patient O O
satisfaction O O
with O O
treatment O O
, O O
asthma O O
severity O O
and O O
number O O
of O O
potentially O O
inappropriate O O
drug O O
combinations O O
as O O
well O O
as O O
the O O
general O O
practitioners O O
' O O
satisfaction O O
in O O
relation O O
to O O
the O O
performance O O
of O O
the O O
QC O O
. O O

A O O
significant O O
improvement O O
in O O
the O O
treatment O O
of O O
asthma O O
was O O
observed O O
in O O
both O O
trial O O
arms O O
. O O

However O O
, O O
there O O
was O O
only O O
a O O
slight O O
improvement O O
regarding O O
inappropriate O O
drug O O
combinations O O
. O O

There O O
were O O
no O O
relevant O O
differences O O
between O O
the O O
group O O
with O O
open O O
benchmark O O
( O O
B-QC O O
) O O
and O O
traditional O O
quality O O
circles O O
( O O
T-QC O O
) O O
. O O

The O O
physicians O O
' O O
satisfaction O O
with O O
the O O
QC O O
performance O O
was O O
significantly O O
higher O O
in O O
the O O
T-QCs O O
. O O

General O O
practitioners O O
seem O O
to O O
take O O
a O O
critical O O
perspective O O
about O O
open O O
benchmarking O O
in O O
quality O O
circles O O
. O O

Caution O O
should O O
be O O
used O O
when O O
implementing O O
benchmarking O O
in O O
a O O
quality O O
circle O O
as O O
it O O
did O O
not O O
improve O O
healthcare O O
when O O
compared O O
to O O
the O O
traditional O O
procedure O O
with O O
anonymised O O
comparisons O O
. O O

ABC O O
transporters O O
influence O O
sensitivity O O
of O O
Brugia O O
malayi O O
to O O
moxidectin B-drug_n B-drug
and O O
have O O
potential O O
roles O O
in O O
drug O O
resistance O O
. O O

Some O O
ABC O O
transporters O O
play O O
a O O
significant O O
role O O
in O O
human O O
health O O
and O O
illness O O
because O O
they O O
confer O O
multidrug O O
resistance O O
( O O
MDR O O
) O O
through O O
their O O
overexpression O O
. O O

Compounds O O
that O O
inhibit O O
the O O
drug O O
efflux O O
mechanism O O
can O O
improve O O
efficacy O O
or O O
reverse O O
resistance O O
. O O

Of O O
the O O
eight O O
described O O
ABC O O
transporter O O
subfamilies O O
, O O
those O O
proteins O O
conferring O O
MDR O O
in O O
humans O O
are O O
in O O
subfamilies O O
A O O
, O O
B O O
, O O
C O O
, O O
and O O
G O O
. O O

In O O
nematodes O O
, O O
transporters O O
in O O
subfamilies O O
B O O
and O O
C O O
are O O
suggested O O
to O O
confer O O
resistance O O
to O O
ivermectin B-drug B-drug
. O O

The O O
Brugia O O
malayi O O
ABC O O
transporter O O
superfamily O O
was O O
examined O O
to O O
assess O O
their O O
potential O O
to O O
influence O O
sensitivity O O
to O O
moxidectin B-drug_n B-drug
. O O

There O O
was O O
an O O
increase O O
in O O
expression O O
of O O
ABC O O
transporters O O
in O O
subfamilies O O
A O O
, O O
B O O
, O O
C O O
, O O
and O O
G O O
following O O
treatment O O
. O O

Co-administration O O
of O O
moxidectin B-drug_n B-drug
with O O
inhibitors O O
of O O
ABC O O
transporter O O
function O O
did O O
not O O
enhance O O
sensitivity O O
to O O
moxidectin B-drug_n B-drug_n
in O O
males O O
; O O

however O O
, O O
sensitivity O O
was O O
significantly O O
enhanced O O
in O O
females O O
and O O
microfilariae O O
. O O

The O O
work O O
suggests O O
that O O
ABC O O
transporters O O
influence O O
sensitivity O O
to O O
moxidectin B-drug_n B-drug
and O O
have O O
a O O
potential O O
role O O
in O O
drug O O
resistance O O
. O O

The O O
role O O
of O O
interneurons O O
in O O
shaping O O
Purkinje O O
cell O O
responses O O
in O O
the O O
cerebellar O O
cortex O O
. O O

The O O
well O O
established O O
anatomy O O
of O O
the O O
cerebellar O O
cortex O O
has O O
led O O
to O O
suggestions O O
that O O
cerebellar O O
molecular O O
layer O O
interneurons O O
laterally O O
inhibit O O
Purkinje O O
cells O O
. O O

In O O
support O O
of O O
the O O
anatomical O O
predictions O O
, O O
on-beam O O
excitation O O
and O O
off-beam O O
inhibition O O
of O O
Purkinje O O
cells O O
have O O
been O O
shown O O
to O O
occur O O
when O O
the O O
surface O O
of O O
the O O
cerebellum O O
is O O
electrically O O
excited O O
. O O

Patchy O O
excitation O O
of O O
Purkinje O O
cells O O
with O O
flanking O O
inhibition O O
of O O
sagittally O O
oriented O O
Purkinje O O
cells O O
have O O
also O O
been O O
demonstrated O O
following O O
peripheral O O
stimulation O O
in O O
vivo O O
. O O

To O O
extend O O
these O O
observations O O
, O O
we O O
mapped O O
the O O
functional O O
connectivity O O
between O O
granule O O
cells O O
, O O
molecular O O
layer O O
interneurons O O
, O O
and O O
Purkinje O O
cells O O
in O O
rats O O
. O O

Patches O O
of O O
granule O O
cells O O
were O O
asynchronously O O
activated O O
by O O
photostimulation O O
to O O
mimic O O
their O O
excitation O O
by O O
a O O
mossy O O
fiber O O
as O O
it O O
occurs O O
in O O
vivo O O
. O O

We O O
found O O
with O O
remarkable O O
consistency O O
that O O
, O O
in O O
the O O
sagittal O O
orientation O O
, O O
granule O O
cells O O
elicit O O
a O O
stereotypic O O
set O O
of O O
responses O O
. O O

Granule O O
cells O O
immediately O O
underneath O O
a O O
Purkinje O O
cell O O
provide O O
pure O O
excitation O O
. O O

Granule O O
cells O O
positioned O O
340-400 O O
m O O
laterally O O
provided O O
pure O O
inhibition O O
, O O
consistent O O
with O O
the O O
lateral O O
inhibition O O
proposed O O
earlier O O
. O O

The O O
net O O
effect O O
of O O
exciting O O
granule O O
cells O O
in O O
between O O
these O O
two O O
extremes O O
was O O
to O O
provide O O
a O O
systematic O O
change O O
in O O
the O O
response O O
of O O
Purkinje O O
cells O O
, O O
from O O
net O O
excitation O O
to O O
net O O
inhibition O O
moving O O
laterally O O
from O O
the O O
Purkinje O O
cell O O
. O O

In O O
contrast O O
to O O
the O O
sagittal O O
orientation O O
, O O
in O O
the O O
coronal O O
orientation O O
the O O
organization O O
of O O
Purkinje O O
cell O O
responses O O
with O O
granule O O
cell O O
activation O O
was O O
remarkably O O
different O O
. O O

Independent O O
of O O
the O O
location O O
of O O
granule O O
cells O O
, O O
within O O
the O O
480 O O
m O O
lateral O O
distance O O
examined O O
, O O
molecular O O
layer O O
interneurons O O
reduced O O
the O O
strength O O
of O O
granule O O
cell O O
inputs O O
to O O
Purkinje O O
cells O O
to O O
a O O
comparable O O
extent O O
. O O

The O O
influence O O
of O O
chemical O O
activation O O
on O O
tooth O O
bleaching O O
using O O
10 O O
% O O
carbamide B-drug_n B-drug
peroxide I-drug_n I-drug
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
assess O O
the O O
influence O O
of O O
manganese B-drug_n O
gluconate I-drug_n B-drug
, O O
a O O
chemical O O
activator O O
of O O
bleaching O O
agents O O
, O O
at O O
a O O
concentration O O
of O O
0.01 O O
% O O
on O O
the O O
efficiency O O
of O O
a O O
10 O O
% O O
carbamide B-drug_n O
peroxide-based O O
bleaching O O
agent O O
. O O

Forty O O
bovine O O
incisors O O
were O O
immersed O O
in O O
a O O
25 O O
% O O
instant O O
coffee O O
solution O O
for O O
seven O O
days O O
and O O
randomly O O
divided O O
into O O
two O O
groups O O
. O O

Group O O
1 O O
was O O
the O O
control O O
group O O
and O O
consisted O O
of O O
10 O O
% O O
carbamide B-drug_n B-drug
peroxide-based O O
bleaching O O
gel O O
only O O
. O O

Group O O
2 O O
consisted O O
of O O
10 O O
% O O
carbamide B-drug_n B-drug
peroxide-based O O
bleaching O O
gel O O
and O O
0.01 O O
% O O
manganese B-drug_n O
gluconate I-drug_n B-drug
. O O

Three O O
readings O O
of O O
color O O
were O O
taken O O
using O O
the O O
Vita O O
Easyshade O O
spectrophotometer O O
: O O
the O O
initial O O
reading O O
, O O
a O O
reading O O
at O O
seven O O
days O O
, O O
and O O
a O O
reading O O
at O O
14 O O
days O O
. O O

Total O O
color O O
variation O O
was O O
calculated O O
by O O
E*Lab O O
. O O

Data O O
were O O
submitted O O
to O O
the O O
statistical O O
t-test O O
( O O
5 O O
% O O
) O O
, O O
which O O
showed O O
that O O
after O O
seven O O
days O O
group O O
2 O O
had O O
a O O
significant O O
increase O O
in O O
the O O
degree O O
of O O
tooth O O
bleaching O O
compared O O
with O O
group O O
1 O O
. O O

The O O
mean O O
values O O
( O O
SD O O
) O O
were O O
16.33 O O
( O O
3.95 O O
) O O
for O O
group O O
1 O O
and O O
19.29 O O
( O O
4.97 O O
) O O
for O O
group O O
2 O O
. O O

However O O
, O O
the O O
results O O
for O O
group O O
1 O O
and O O
group O O
2 O O
were O O
similar O O
after O O
14 O O
days O O
. O O

Adding O O
0.01 O O
% O O
manganese B-drug_n O
gluconate I-drug_n B-drug
to O O
10 O O
% O O
carbamide B-drug_n B-drug
peroxide I-drug_n I-drug
bleaching O O
gel O O
increased O O
the O O
degree O O
of O O
tooth O O
bleaching O O
after O O
a O O
seven-day O O
treatment O O
and O O
did O O
not O O
influence O O
the O O
resulting O O
shade O O
after O O
14 O O
days O O
. O O

Novel O O
insights O O
into O O
the O O
synergistic O O
interaction O O
of O O
Bortezomib B-drug B-drug
and O O
TRAIL O B-drug_n
: O O
tBid O O
provides O O
the O O
link O O
. O O

The O O
proteasome O O
inhibitor O O
Bortezomib B-drug B-drug
has O O
been O O
identified O O
as O O
a O O
potent O O
enhancer O O
of O O
TRAIL-induced O O
apoptosis O O
in O O
several O O
human O O
cancers O O
. O O

However O O
, O O
the O O
identification O O
of O O
the O O
underlying O O
molecular O O
mechanisms O O
of O O
this O O
synergistic O O
cell O O
death O O
induction O O
has O O
been O O
ongoing O O
over O O
the O O
last O O
years O O
. O O

A O O
recent O O
study O O
identifies O O
a O O
new O O
mechanism O O
of O O
action O O
for O O
the O O
synergism O O
of O O
TRAIL O O
and O O
Bortezomib B-drug B-drug
. O O

Nitric B-drug B-drug
oxide I-drug I-drug
is O O
an O O
activity-dependent O O
regulator O O
of O O
target O O
neuron O O
intrinsic O O
excitability O O
. O O

Activity-dependent O O
changes O O
in O O
synaptic O O
strength O O
are O O
well O O
established O O
as O O
mediating O O
long-term O O
plasticity O O
underlying O O
learning O O
and O O
memory O O
, O O
but O O
modulation O O
of O O
target O O
neuron O O
excitability O O
could O O
complement O O
changes O O
in O O
synaptic O O
strength O O
and O O
regulate O O
network O O
activity O O
. O O

It O O
is O O
thought O O
that O O
homeostatic O O
mechanisms O O
match O O
intrinsic O O
excitability O O
to O O
the O O
incoming O O
synaptic O O
drive O O
, O O
but O O
evidence O O
for O O
involvement O O
of O O
voltage-gated O O
conductances O O
is O O
sparse O O
. O O

Here O O
, O O
we O O
show O O
that O O
glutamatergic O O
synaptic O O
activity O O
modulates O O
target O O
neuron O O
excitability O O
and O O
switches O O
the O O
basis O O
of O O
action O O
potential O O
repolarization O O
from O O
Kv3 O O
to O O
Kv2 O O
potassium O O
channel O O
dominance O O
, O O
thereby O O
adjusting O O
neuronal O O
signaling O O
between O O
low O O
and O O
high O O
activity O O
states O O
, O O
respectively O O
. O O

This O O
nitric O O
oxide-mediated O O
signaling O O
dramatically O O
increases O O
Kv2 O O
currents O O
in O O
both O O
the O O
auditory O O
brain O O
stem O O
and O O
hippocampus O O
( O O
& O O
gt O O
; O O
3-fold O O
) O O
transforming O O
synaptic O O
integration O O
and O O
information O O
transmission O O
but O O
with O O
only O O
modest O O
changes O O
in O O
action O O
potential O O
waveform O O
. O O

We O O
conclude O O
that O O
nitric O B-drug
oxide O I-drug
is O O
a O O
homeostatic O O
regulator O O
, O O
tuning O O
neuronal O O
excitability O O
to O O
the O O
recent O O
history O O
of O O
excitatory O O
synaptic O O
inputs O O
over O O
intervals O O
of O O
minutes O O
to O O
hours O O
. O O

Spontaneous O O
spiking O O
and O O
synaptic O O
depression O O
underlie O O
noradrenergic O O
control O O
of O O
feed-forward O O
inhibition O O
. O O

Inhibitory O O
interneurons O O
across O O
diverse O O
brain O O
regions O O
commonly O O
exhibit O O
spontaneous O O
spiking O O
activity O O
, O O
even O O
in O O
the O O
absence O O
of O O
external O O
stimuli O O
. O O

It O O
is O O
not O O
well O O
understood O O
how O O
stimulus-evoked O O
inhibition O O
can O O
be O O
distinguished O O
from O O
background O O
inhibition O O
arising O O
from O O
spontaneous O O
firing O O
. O O

We O O
found O O
that O O
noradrenaline O B-drug
simultaneously O O
reduced O O
spontaneous O O
inhibitory O O
inputs O O
and O O
enhanced O O
evoked O O
inhibitory O O
currents O O
recorded O O
from O O
principal O O
neurons O O
of O O
the O O
mouse O O
dorsal O O
cochlear O O
nucleus O O
( O O
DCN O O
) O O
. O O

Together O O
, O O
these O O
effects O O
produced O O
a O O
large O O
increase O O
in O O
signal-to-noise O O
ratio O O
for O O
stimulus-evoked O O
inhibition O O
. O O

Surprisingly O O
, O O
the O O
opposing O O
effects O O
on O O
background O O
and O O
evoked O O
currents O O
could O O
both O O
be O O
attributed O O
to O O
noradrenergic O O
silencing O O
of O O
spontaneous O O
spiking O O
in O O
glycinergic O O
interneurons O O
. O O

During O O
spontaneous O O
firing O O
, O O
glycine O B-drug
release O O
was O O
decreased O O
due O O
to O O
strong O O
short-term O O
depression O O
. O O

Elimination O O
of O O
background O O
spiking O O
relieved O O
inhibitory O O
synapses O O
from O O
depression O O
and O O
thereby O O
enhanced O O
stimulus-evoked O O
inhibition O O
. O O

Our O O
findings O O
illustrate O O
a O O
simple O O
yet O O
powerful O O
neuromodulatory O O
mechanism O O
to O O
shift O O
the O O
balance O O
between O O
background O O
and O O
stimulus-evoked O O
signals O O
. O O

Approach O O
to O O
the O O
evaluation O O
of O O
a O O
patient O O
with O O
an O O
increased O O
serum O O
osmolal O O
gap O O
and O O
high-anion-gap O O
metabolic O O
acidosis O O
. O O

An O O
increase O O
in O O
serum O O
osmolality O O
and O O
serum O O
osmolal O O
gap O O
with O O
or O O
without O O
high-anion-gap O O
metabolic O O
acidosis O O
is O O
an O O
important O O
clue O O
to O O
exposure O O
to O O
one O O
of O O
the O O
toxic O O
alcohols O O
, O O
which O O
include O O
methanol B-drug_n B-drug
, O O
ethylene B-drug_n B-drug
glycol I-drug_n I-drug
, O O
diethylene B-drug_n B-drug
glycol I-drug_n I-drug
, O O
propylene B-drug_n B-drug
glycol I-drug_n I-drug
, O O
or O O
isopropanol B-drug B-drug
. O O

However O O
, O O
the O O
increase O O
in O O
serum O O
osmolal O O
gap O O
and O O
metabolic O O
acidosis O O
can O O
occur O O
either O O
together O O
or O O
alone O O
depending O O
on O O
several O O
factors O O
, O O
including O O
baseline O O
serum O O
osmolal O O
gap O O
, O O
molecular O O
weight O O
of O O
the O O
alcohol O B-drug
, O O
and O O
stage O O
of O O
metabolism O O
of O O
the O O
alcohol O B-drug
. O O

In O O
addition O O
, O O
other O O
disorders O O
, O O
including O O
diabetic O O
or O O
alcoholic O O
ketoacidosis O O
, O O
acute O O
kidney O O
injury O O
, O O
chronic O O
kidney O O
disease O O
, O O
and O O
lactic O O
acidosis O O
, O O
can O O
cause O O
high-anion-gap O O
metabolic O O
acidosis O O
associated O O
with O O
an O O
increased O O
serum O O
osmolal O O
gap O O
and O O
therefore O O
should O O
be O O
explored O O
in O O
the O O
differential O O
diagnosis O O
. O O

It O O
is O O
essential O O
for O O
clinicians O O
to O O
understand O O
the O O
value O O
and O O
limitations O O
of O O
osmolal O B-drug_n
gap O O
to O O
assist O O
in O O
reaching O O
the O O
correct O O
diagnosis O O
and O O
initiating O O
appropriate O O
treatment O O
. O O

In O O
this O O
teaching O O
case O O
, O O
we O O
present O O
a O O
systematic O O
approach O O
to O O
diagnosing O O
high O O
serum O O
osmolality O O
and O O
increased O O
serum O O
osmolal O O
gap O O
with O O
or O O
without O O
high-anion-gap O O
metabolic O O
acidosis O O
. O O

Pharmacological O O
drugs O O
inducing O O
ototoxicity O O
, O O
vestibular O O
symptoms O O
and O O
tinnitus O O
: O O
a O O
reasoned O O
and O O
updated O O
guide O O
. O O

The O O
present O O
work O O
on O O
drug-induced O O
ototoxicity O O
, O O
tinnitus O O
and O O
vertigo O O
represents O O
the O O
update O O
and O O
revision O O
of O O
a O O
previous O O
guide O O
to O O
adverse O O
drug O O
reactions O O
for O O
italian O O
physicians O O
( O O
2005 O O
) O O
. O O

The O O
panorama O O
of O O
drug-induced O O
side O O
effects O O
causing O O
ototoxicity O O
or O O
symptoms O O
such O O
as O O
tinnitus O O
or O O
dizziness O O
and O O
vertigo O O
has O O
enlarged O O
in O O
recent O O
years O O
, O O
thanks O O
to O O
a O O
better O O
knowledge O O
and O O
a O O
more O O
specific O O
attention O O
of O O
pharmaceutical O O
firms O O
and O O
drug-control O O
institutions O O
. O O

In O O
daily O O
clinical O O
practice O O
, O O
there O O
is O O
a O O
need O O
for O O
the O O
family O O
physician O O
and O O
the O O
ENT O O
specialist O O
or O O
audiologist O O
( O O
also O O
in O O
consideration O O
of O O
the O O
possible O O
medico-legal O O
implications O O
) O O
to O O
focus O O
the O O
attention O O
on O O
the O O
possible O O
risk O O
of O O
otological O O
side O O
effects O O
. O O

This O O
would O O
allow O O
a O O
clinical O O
risk-benefit O O
evaluation O O
, O O
weighing O O
the O O
possible O O
clinical O O
advantage O O
in O O
their O O
field O O
of O O
competence O O
against O O
possible O O
otological O O
side-effects O O
. O O

The O O
list O O
of O O
active O O
ingredients O O
and O O
drugs O O
is O O
subdivided O O
in O O
categories O O
based O O
on O O
their O O
audiological O O
and O O
otoneurological O O
side-effects O O
, O O
that O O
have O O
been O O
signaled O O
by O O
the O O
drug O O
companies O O
and/or O O
ministerial O O
notes O O
. O O

Drugs O O
have O O
also O O
been O O
subcategorized O O
with O O
regards O O
to O O
the O O
field O O
in O O
which O O
they O O
are O O
applied O O
, O O
the O O
therapeutic O O
indications O O
and O O
the O O
clinical O O
behaviour O O
. O O

They O O
have O O
also O O
been O O
organized O O
in O O
alphabetical O O
order O O
, O O
for O O
an O O
easier O O
consultation O O
. O O

The O O
guide O O
above O O
, O O
even O O
if O O
initially O O
conceived O O
for O O
being O O
used O O
in O O
Italy O O
, O O
also O O
presents O O
a O O
more O O
general O O
and O O
international O O
interest O O
, O O
expecially O O
as O O
for O O
as O O
the O O
concepts O O
of O O
pharmacology O O
and O O
the O O
features O O
of O O
the O O
active O O
ingredients O O
are O O
concerned O O
. O O

The O O
guide O O
is O O
, O O
therefore O O
, O O
useful O O
as O O
for O O
as O O
we O O
are O O
concerned O O
to O O
any O O
physician O O
, O O
regardless O O
of O O
the O O
country O O
he/she O O
operates O O
in O O
. O O

[ O O
Ticagrelor B-drug B-drug
: O O
a O O
novel O O
antiplatelet B-group B-group
agent I-group I-group
for O O
patients O O
with O O
acute O O
coronary O O
syndrome O O
] O O
. O O

Ticagrelor B-drug B-drug_n
is O O
an O O
oral O O
, O O
reversible O O
blocker O O
of O O
the O O
P2Y12 O O
adenosine O O
receptor O O
. O O

In O O
clinical O O
trials O O
the O O
antiplatelet B-group B-group
agent I-group I-group
reduced O O
significantly O O
vascular O O
mortality O O
and O O
death O O
from O O
any O O
cause O O
when O O
compared O O
to O O
clopidogrel B-drug B-drug
in O O
patients O O
with O O
acute O O
coronary O O
syndrome O O
. O O

[ O O
Infections O O
with O O
human O O
immunodeficiency O O
viruses O O
. O O
Part O O
II O O
: O O
Antiretroviral B-group B-group
drugs I-group I-group
, O O
therapeutic O O
options O O
, O O
and O O
diagnostics O O
] O O
. O O

Infections O O
with O O
the O O
human O O
immunodeficiency O O
virus O O
1 O O
( O O
HIV- O O
1 O O
) O O
lead O O
to O O
the O O
acquired O O
immunodeficiency O O
syndrome O O
( O O
AIDS O O
) O O
, O O
resulting O O
in O O
the O O
establishment O O
of O O
a O O
wide O O
range O O
of O O
severe O O
opportunistic O O
infections O O
. O O

Since O O
the O O
introduction O O
of O O
the O O
highly B-group B-group
active I-group I-group
antiretroviral I-group I-group
therapy O O
( O O
HAART O O
) O O
into O O
the O O
treatment O O
of O O
HIV O O
infections O O
, O O
in O O
many O O
cases O O
a O O
delayed O O
appearance O O
of O O
AIDS-defining O O
diseases O O
is O O
achievable O O
. O O

Life O O
expectancy O O
of O O
antiretrovirally O O
treated O O
HIV-infected O O
people O O
applying O O
HAART O O
could O O
be O O
considerably O O
extended O O
and O O
now O O
resembles O O
that O O
of O O
several O O
other O O
chronic O O
diseases O O
. O O

For O O
the O O
initial O O
treatment O O
of O O
HIV-1 O O
infection O O
, O O
an O O
adjunction O O
with O O
three O O
antiretroviral B-group B-group
agents I-group I-group
is O O
generally O O
used O O
. O O

In O O
most O O
cases O O
, O O
the O O
application O O
of O O
two O O
nucleoside B-group O
or I-group O
nucleotide I-group B-group
reverse I-group I-group
transcriptase I-group I-group
inhibitors I-group I-group
( O O
NRTI B-group O
) O O
together O O
with O O
a O O
non-nucleoside B-group B-group
reverse I-group I-group
transcriptase I-group I-group
inhibitor I-group I-group
( O O
NNRTI B-group B-group
) O O
, O O
a O O
protease B-group B-group
inhibitor I-group I-group
( O O
PI B-group O
) O O
or O O
an O O
integrase B-group B-group
inhibitor I-group I-group
( O O
II B-group O
) O O
is O O
recommended O O
. O O

Before O O
and O O
during O O
antiretroviral B-group B-group
treatment O O
, O O
antiretroviral B-group B-group
drug O I-group
resistances O O
, O O
individual O O
tolerance O O
profiles O O
and O O
the O O
needs O O
of O O
the O O
individual O O
patient O O
, O O
as O O
well O O
as O O
several O O
interactions O O
with O O
other O O
drugs O O
have O O
to O O
be O O
considered O O
. O O

Diagnostics O O
of O O
HIV O O
infection O O
is O O
based O O
upon O O
the O O
proof O O
of O O
specific O O
antibodies O O
. O O

Identification O O
of O O
a O O
dopamine O O
receptor-mediated O O
opiate B-group B-group
reward O O
memory O O
switch O O
in O O
the O O
basolateral O O
amygdala-nucleus O O
accumbens O O
circuit O O
. O O

The O O
basolateral O O
amygdala O O
( O O
BLA O O
) O O
, O O
ventral O O
tegmental O O
area O O
( O O
VTA O O
) O O
, O O
and O O
nucleus O O
accumbens O O
( O O
NAc O O
) O O
play O O
central O O
roles O O
in O O
the O O
processing O O
of O O
opiate-related B-group B-group
associative O O
reward O O
learning O O
and O O
memory O O
. O O

The O O
BLA O O
receives O O
innervation O O
from O O
dopaminergic O O
fibers O O
originating O O
in O O
the O O
VTA O O
, O O
and O O
both O O
dopamine O B-drug
( O O
DA O O
) O O
D1 O O
and O O
D2 O O
receptors O O
are O O
expressed O O
in O O
this O O
region O O
. O O

Using O O
a O O
combination O O
of O O
in O O
vivo O O
single-unit O O
extracellular O O
recording O O
in O O
the O O
NAc O O
combined O O
with O O
behavioral O O
pharmacology O O
studies O O
, O O
we O O
have O O
identified O O
a O O
double O O
dissociation O O
in O O
the O O
functional O O
roles O O
of O O
DA O O
D1 O O
versus O O
D2 O O
receptor O O
transmission O O
in O O
the O O
BLA O O
, O O
which O O
depends O O
on O O
opiate B-group B-group
exposure O O
state O O
; O O

thus O O
, O O
in O O
previously O O
opiate-naive B-group O
rats O O
, O O
blockade O O
of O O
intra-BLA O O
D1 O O
, O O
but O O
not O O
D2 O O
, O O
receptor O O
transmission O O
blocked O O
the O O
acquisition O O
of O O
associative O O
opiate O B-group
reward O O
memory O O
, O O
measured O O
in O O
an O O
unbiased O O
conditioned O O
place O O
preference O O
procedure O O
. O O

In O O
direct O O
contrast O O
, O O
in O O
rats O O
made O O
opiate B-group B-group
dependent O O
and O O
conditioned O O
in O O
a O O
state O O
of O O
withdrawal O O
, O O
intra-BLA O O
D2 O O
, O O
but O O
not O O
D1 O O
, O O
receptor O O
blockade O O
blocked O O
opiate B-group B-group
reward O O
encoding O O
. O O

This O O
functional O O
switch O O
was O O
dependent O O
on O O
cAMP O O
signaling O O
as O O
comodulation O O
of O O
intra-BLA O O
cAMP O O
levels O O
reversed O O
or O O
replicated O O
the O O
functional O O
effects O O
of O O
intra-BLA O O
D1 O O
or O O
D2 O O
transmission O O
during O O
opiate B-group B-group
reward O O
processing O O
. O O

Single-unit O O
in O O
vivo O O
extracellular O O
recordings O O
performed O O
in O O
neurons O O
of O O
the O O
NAc O O
confirmed O O
an O O
opiate-state-dependent B-group B-drug_n
role O O
for O O
BLA O O
D1/D2 O O
transmission O O
in O O
NAc O O
neuronal O O
response O O
patterns O O
to O O
morphine B-drug B-drug
. O O

Our O O
results O O
characterize O O
and O O
identify O O
a O O
novel O O
opiate B-group B-group
addiction O O
switching O O
mechanism O O
directly O O
in O O
the O O
BLA O O
that O O
can O O
control O O
the O O
processing O O
of O O
opiate B-group B-group
reward O O
information O O
as O O
a O O
direct O O
function O O
of O O
opiate B-group B-group
exposure O O
state O O
via O O
D1 O O
or O O
D2 O O
receptor O O
signaling O O
substrates O O
. O O

Potential O O
underuse O O
, O O
overuse O O
, O O
and O O
inappropriate O O
use O O
of O O
antidepressants B-group B-group
in O O
older O O
veteran O O
nursing O O
home O O
residents O O
. O O

To O O
examine O O
prevalence O O
and O O
resident- O O
and O O
site-level O O
factors O O
associated O O
with O O
potential O O
underuse O O
, O O
overuse O O
, O O
and O O
inappropriate O O
use O O
of O O
antidepressants B-group B-group
in O O
older O O
Veterans O O
Affairs O O
( O O
VA O O
) O O
Community O O
Living O O
Center O O
( O O
CLC O O
) O O
residents O O
. O O

Longitudinal O O
study O O
. O O

One O O
hundred O O
thirty-three O O
VA O O
CLCs O O
. O O

Three O O
thousand O O
six O O
hundred O O
ninety-two O O
veterans O O
aged O O
65 O O
and O O
older O O
admitted O O
between O O
January O O
1 O O
, O O
2004 O O
, O O
and O O
June O O
3 O O
, O O
2005 O O
, O O
with O O
long O O
stays O O
( O O
90 O O
days O O
) O O
. O O

Prevalence O O
of O O
potential O O
underuse O O
, O O
inappropriate O O
use O O
, O O
and O O
overuse O O
of O O
antidepressants B-group B-group
in O O
residents O O
with O O
and O O
without O O
depression O O
( O O
as O O
documented O O
according O O
to O O
International O O
Classification O O
of O O
Diseases O O
, O O
Ninth O O
Revision O O
, O O
Clinical O O
Modification O O
, O O
codes O O
or O O
Depression O O
Rating O O
Scale O O
) O O
. O O

Selective B-group B-group
serotonin I-group I-group
reuptake I-group I-group
inhibitors I-group I-group
were O O
the O O
most O O
commonly O O
prescribed O O
antidepressant B-group B-group
. O O

Of O O
the O O
877 O O
residents O O
with O O
depression O O
, O O
25.4 O O
% O O
did O O
not O O
receive O O
an O O
antidepressant B-group B-group
, O O
suggesting O O
potential O O
underuse O O
. O O

Of O O
residents O O
with O O
depression O O
who O O
received O O
antidepressants B-group B-group
, O O
57.5 O O
% O O
had O O
potential O O
inappropriate O O
use O O
due O O
primarily O O
to O O
problems O O
seen O O
with O O
drug-drug O O
and O O
drug-disease O O
interactions O O
. O O

Of O O
the O O
2,815 O O
residents O O
who O O
did O O
not O O
have O O
depression O O
, O O
1,190 O O
( O O
42.3 O O
% O O
) O O
were O O
prescribed O O
one O O
or O O
more O O
antidepressants B-group B-group
; O O

only O O
48 O O
( O O
4.0 O O
% O O
) O O
of O O
these O O
had O O
a O O
Food O O
and O O
Drug O O
Administration-approved O O
labeled O O
indication O O
, O O
suggesting O O
potential O O
overuse O O
. O O

Overall O O
, O O
only O O
17.6 O O
% O O
of O O
antidepressant B-group B-group
use O O
was O O
appropriate O O
( O O
324/1,844 O O
) O O
. O O

The O O
only O O
consistent O O
resident O O
factor O O
associated O O
with O O
potential O O
underuse O O
and O O
overuse O O
use O O
was O O
taking O O
an O O
antipsychotic B-group B-group
without O O
evidence O O
of O O
schizophrenia O O
( O O
underuse O O
: O O
adjusted O O
relative O O
risk O O
ratio O O
( O O
ARRR O O
) O O
=0.56 O O
, O O
95 O O
% O O
confidence O O
interval O O
( O O
CI O O
) O O
=0.33-0.94 O O
; O O
overuse O O
: O O
adjusted O O
odds O O
ratio=1.52 O O
, O O
95 O O
% O O
CI=1.21-1.91 O O
) O O
. O O

Having O O
moderate O O
to O O
severe O O
pain O O
( O O
ARRR=1.54 O O
, O O
95 O O
% O O
CI=1.08-2.20 O O
) O O
and O O
the O O
prescribing O O
of O O
an O O
anxiolytic B-group B-group
or O O
hypnotic B-group B-group
( O O
ARRR=1.33 O O
, O O
95 O O
% O O
CI=1.02-1.74 O O
) O O
increased O O
the O O
risk O O
of O O
potential O O
inappropriate O O
antidepressant B-group B-group
use O O
. O O

Potential O O
problems O O
with O O
the O O
use O O
of O O
antidepressants B-group B-group
were O O
frequently O O
observed O O
in O O
older O O
U.S O O
. O O

veteran O O
CLC O O
residents O O
. O O

Future O O
studies O O
are O O
needed O O
to O O
examine O O
the O O
true O O
risks O O
and O O
benefits O O
of O O
antidepressant B-group B-group
use O O
in O O
CLC O O
and O O
non-VA O O
nursing O O
homes O O
. O O

Treatment O O
of O O
nicotine B-drug B-drug
dependence O O
with O O
Chantix B-brand B-brand
( O O
varenicline B-drug B-drug
) O O
. O O

Varenicline B-drug B-drug
is O O
the O O
generic O O
name O O
for O O
Chantix B-brand B-brand
, O O
the O O
newest O O
drug O O
available O O
for O O
the O O
treatment O O
of O O
tobacco O O
dependence O O
. O O

In O O
a O O
randomized O O
controlled O O
clinical O O
trial O O
, O O
the O O
abstinence O O
rate O O
at O O
1 O O
year O O
for O O
patients O O
using O O
varencline B-drug B-drug
was O O
superior O O
to O O
that O O
of O O
patients O O
in O O
the O O
group O O
using O O
bupropion B-drug B-drug
SR I-drug I-drug
( O O
Zyban B-brand B-brand
) O O
and O O
in O O
the O O
placebo O O
group O O
( O O
11 O O
) O O
. O O

Varenicline B-drug B-drug
reduces O O
nicotine B-drug B-drug
withdrawal O O
symptoms O O
, O O
cigarette O O
craving O O
and O O
nicotine B-drug B-drug
satisfaction O O
. O O

Post-market O O
reports O O
prompted O O
a O O
warning O O
of O O
serious O O
adverse O O
neuropsychiatric O O
events O O
in O O
patients O O
taking O O
varenicline B-drug B-drug
. O O

As O O
is O O
the O O
case O O
with O O
any O O
surgical O O
procedure O O
and/or O O
prescription O O
medication O O
, O O
full O O
disclosure O O
of O O
the O O
risks O O
and O O
benefits O O
should O O
be O O
discussed O O
with O O
the O O
patient O O
. O O

The O O
significant O O
health O O
benefits O O
of O O
quitting O O
smoking O O
should O O
be O O
weighed O O
against O O
the O O
individual O O
's O O
risk O O
of O O
adverse O O
events O O
associated O O
with O O
the O O
use O O
of O O
varenicline B-drug B-drug
for O O
smoking O O
cessation O O
. O O

[ O O
Study O O
on O O
synergic O O
and O O
decreasing O O
toxic O O
effects O O
of O O
mineral O O
water O O
and O O
Chinese O O
herbal O O
compound O O
preparation O O
on O O
cisplatin B-drug B-drug
] O O
. O O

The O O
synergic O O
and O O
decreasing O O
toxic O O
effects O O
of O O
mineral O O
water O O
and O O
Chinese O O
herbal O O
compound O O
preparation O O
( O O
MWCHCP O B-brand
) O O
on O O
cisplatin B-drug B-drug
were O O
investigated O O
in O O
sarcoma O O
180 O O
( O O
S180 O O
) O O
mice O O
. O O

The O O
S180 O O
mice O O
were O O
treated O O
for O O
5 O O
days O O
with O O
intraperitoneal O O
injection O O
of O O
cisplatin B-drug B-drug
( O O
7.33 O O
mg O O
x O O
kg O O
( O O
-1 O O
) O O
) O O
and O O
oral O O
administration O O
of O O
MWCHCP O B-brand
( O O
1 O O
925 O O
, O O
3 O O
850 O O
, O O
7 O O
700 O O
mg O O
x O O
kg O O
( O O
-1 O O
) O O
) O O
. O O

Then O O
the O O
mice O O
were O O
killed O O
and O O
the O O
tumor O O
growth O O
inhibition O O
rate O O
, O O
organ O O
index O O
, O O
diarrhea O O
index O O
were O O
determined O O
. O O

Observe O O
pathological O O
sections O O
of O O
stomach O O
to O O
study O O
the O O
protective O O
effect O O
of O O
MWCHCP O B-brand
. O O

Reverse O O
transcription-polymerase O O
chain O O
reaction O O
( O O
RT-PCR O O
) O O
was O O
applied O O
to O O
investigate O O
the O O
tumour O O
necrosis O O
factor-alpha O O
( O O
TNF-alpha O B-drug
) O O
expression O O
level O O
of O O
the O O
intestine O O
. O O

Combining O O
with O O
cisplatin B-drug B-drug
and O O
MWCHCP O B-brand
caused O O
a O O
tendency O O
of O O
increasing O O
the O O
tumor O O
growth O O
inhibition O O
rate O O
and O O
significant O O
attenution O O
of O O
cisplatin-induced B-drug B-drug
diarrhea O O
, O O
visceral O O
organ O O
injury O O
, O O
gastric O O
mucosal O O
injury O O
and O O
decreased O O
TNF-alpha O B-drug
mRNA O O
level O O
of O O
intestine O O
. O O

The O O
present O O
findings O O
suggest O O
that O O
MWCHCP O B-brand
increases O O
the O O
inhibition O O
rate O O
of O O
tumor O O
growth O O
of O O
cisplatin B-drug B-drug
and O O
has O O
a O O
beneficial O O
influence O O
on O O
gastrointestinal O O
lesion O O
induced O O
by O O
cisplatin B-drug B-drug
. O O

CPP-ACP B-drug_n O
complex I-drug_n O
as O O
a O O
new O O
adjunctive O O
agent O O
for O O
remineralisation O O
: O O
a O O
review O O
. O O

In O O
addition O O
to O O
regular O O
professional O O
oral O O
hygiene O O
visits O O
and O O
the O O
application O O
of O O
appropriate O O
preventive O O
medications O O
, O O
successful O O
preventive O O
strategies O O
involve O O
oral O O
health O O
promotion O O
, O O
patient O O
education O O
and O O
patient O O
compliance O O
. O O

The O O
Casein B-drug_n O
phosphopeptide-amorphous I-drug_n O
calcium I-drug_n O
phosphate I-drug_n O
( I-drug_n O
CPP-ACP I-drug_n O
) I-drug_n O
complex I-drug_n O
has O O
been O O
shown O O
to O O
remineralise O O
tooth O O
surfaces O O
in O O
situ O O
when O O
delivered O O
in O O
oral O O
care O O
products O O
. O O

This O O
complex O O
has O O
a O O
unique O O
ability O O
to O O
deliver O O
bio-available O O
calcium B-drug O
and O O
phosphate B-drug O
when O O
they O O
are O O
needed O O
most O O
. O O

The O O
effectiveness O O
of O O
casein O O
derivatives O O
, O O
specifically O O
CCP-ACP B-drug_n O
, O O
in O O
caries O O
prevention O O
and O O
lesion O O
reversal O O
has O O
been O O
supported O O
by O O
many O O
controlled O O
clinical O O
studies O O
. O O

This O O
review O O
summarises O O
the O O
research O O
on O O
Casein B-drug_n O
phosphopeptide-amorphous I-drug_n O
calcium I-drug_n O
phosphate I-drug_n O
complex I-drug_n O
and O O
provides O O
information O O
related O O
to O O
its O O
benefit O O
in O O
dentistry O O
. O O

Further O O
research O O
is O O
required O O
to O O
provide O O
a O O
scientifically O O
supported O O
recommendation O O
for O O
other O O
clinical O O
applications O O
. O O

IGF1R-targeted O O
therapy O O
and O O
its O O
enhancement O O
of O O
doxorubicin B-drug B-drug
chemosensitivity O O
in O O
human O O
osteosarcoma O O
cell O O
lines O O
. O O

Type-I O O
insulin-like O O
growth O O
factor O O
receptor O O
( O O
IGF1R O O
) O O
and O O
its O O
signaling O O
play O O
an O O
important O O
role O O
in O O
osteosarcomagenesis O O
, O O
tumor O O
progression O O
, O O
and O O
chemoresistance O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
investigate O O
both O O
the O O
effect O O
and O O
mechanisms O O
of O O
IGF1R O O
inhibition O O
by O O
tyrphostin B-drug_n B-drug_n
AG1024 I-drug_n O
in O O
the O O
presence O O
or O O
absence O O
of O O
doxorubicin B-drug B-drug
in O O
a O O
panel O O
of O O
six O O
osteosarcoma O O
cell O O
lines O O
and O O
a O O
self-established O O
doxorubicin-resistant B-drug O
cell O O
line O O
. O O

We O O
are O O
the O O
first O O
to O O
indicate O O
that O O
targeting O O
IGF1R O O
together O O
with O O
doxorubicin B-drug B-drug
achieved O O
additive O O
anti-osteosarcoma O O
growth O O
effect O O
, O O
accompanied O O
with O O
increased O O
apoptosis O O
, O O
cytotoxicity O O
, O O
and O O
dual O O
cell O O
cycle O O
arrests O O
. O O

In O O
conclusion O O
, O O
IGF1R O O
inhibition O O
can O O
enhance O O
doxorubicin B-drug B-drug
chemotherapy O O
in O O
some O O
osteosarcoma O O
cell O O
lines O O
. O O

[ O O
Variability O O
of O O
cannabinoid B-drug_n O
findings O O
in O O
blood O O
] O O
. O O

Cannabis O O
products O O
have O O
been O O
administered O O
for O O
many O O
centuries O O
; O O

today O O
, O O
cannabis O O
is O O
the O O
most O O
widely O O
used O O
illegal O O
drug O O
all O O
over O O
the O O
world O O
. O O

Nevertheless O O
, O O
the O O
interpretation O O
of O O
cannabis O O
findings O O
in O O
blood O O
with O O
regard O O
to O O
consumption O O
behaviour O O
and/or O O
estimating O O
the O O
elapsed O O
time O O
since O O
the O O
last O O
cannabis O O
use O O
is O O
still O O
a O O
very O O
challenging O O
task O O
. O O

A O O
wide O O
variation O O
of O O
pharmacokinetic O O
parameters O O
has O O
been O O
observed O O
even O O
in O O
experimental O O
studies O O
. O O

Different O O
chemical O O
structures O O
of O O
precursors O O
, O O
smoking O O
dynamics O O
, O O
pyrolysis O O
of O O
phytocannabinoids B-drug_n O
and O O
frequency O O
of O O
drug O O
use O O
affect O O
the O O
amount O O
of O O
THC B-drug_n O
absorbed O O
. O O

Polymorphic O O
enzymes O O
are O O
involved O O
in O O
phase-I-metabolism O O
of O O
THC B-drug_n O
. O O

Pharmacological O O
effects O O
of O O
other O O
cannabinoids B-drug_n B-group
or O O
medication O O
on O O
the O O
pharmacokinetics O O
of O O
THC B-drug_n B-drug
have O O
not O O
yet O O
been O O
studied O O
in O O
detail O O
. O O

Hydrolysis O O
of O O
cannabis O O
conjugates O O
may O O
occur O O
during O O
storage O O
of O O
blood O O
samples O O
and O O
processing O O
of O O
specimens O O
for O O
analysis O O
; O O

knowledge O O
on O O
the O O
stability O O
of O O
cannabinoids B-drug_n B-group
in O O
forensic O O
specimens O O
is O O
still O O
poor O O
. O O

Whether O O
determination O O
of O O
cannabinoid B-drug_n O
conjugates O O
may O O
be O O
useful O O
is O O
a O O
matter O O
of O O
further O O
consideration O O
. O O

At O O
present O O
, O O
the O O
broad O O
variation O O
of O O
pharmacokinetic O O
parameters O O
and O O
the O O
limiting O O
factors O O
discussed O O
in O O
the O O
present O O
paper O O
should O O
be O O
taken O O
into O O
account O O
when O O
using O O
data O O
from O O
experimental O O
studies O O
for O O
interpretation O O
of O O
analytical O O
results O O
in O O
forensic O O
case O O
work O O
. O O

A O O
circadian O O
clock O O
in O O
hippocampus O O
is O O
regulated O O
by O O
interaction O O
between O O
oligophrenin-1 O B-drug_n
and O O
Rev-erb O B-drug_n
. O O
Oligophrenin-1 O O
regulates O O
dendritic O O
spine O O
morphology O O
in O O
the O O
brain O O
. O O

Mutations O O
in O O
the O O
oligophrenin-1 O O
gene O O
( O O
OPHN1 O O
) O O
cause O O
intellectual O O
disability O O
. O O

We O O
discovered O O
a O O
previously O O
unknown O O
partner O O
of O O
oligophrenin-1 O O
, O O
Rev-erb O O
, O O
a O O
nuclear O O
receptor O O
that O O
represses O O
the O O
transcription O O
of O O
circadian O O
oscillators O O
. O O

We O O
found O O
that O O
oligophrenin-1 O O
interacts O O
with O O
Rev-erb O O
in O O
the O O
mouse O O
brain O O
, O O
causing O O
it O O
to O O
locate O O
to O O
dendrites O O
, O O
reducing O O
its O O
repressor O O
activity O O
and O O
protecting O O
it O O
from O O
degradation O O
. O O

Our O O
results O O
indicate O O
the O O
presence O O
of O O
a O O
circadian O O
oscillator O O
in O O
the O O
hippocampus O O
, O O
involving O O
the O O
clock O O
gene O O
Bmal1 O O
( O O
also O O
known O O
as O O
Arntl O O
) O O
, O O
that O O
is O O
modulated O O
by O O
Rev-erb O O
and O O
requires O O
oligophrenin-1 O O
for O O
normal O O
oscillation O O
. O O

We O O
also O O
found O O
that O O
synaptic O O
activity O O
induced O O
Rev-erb O O
localization O O
to O O
dendrites O O
and O O
spines O O
, O O
a O O
process O O
that O O
is O O
mediated O O
by O O
AMPA O O
receptor O O
activation O O
and O O
requires O O
oligophrenin-1 O O
. O O

Our O O
data O O
reveal O O
new O O
interactions O O
between O O
synaptic O O
activity O O
and O O
circadian O O
oscillators O O
, O O
and O O
delineate O O
a O O
new O O
means O O
of O O
communication O O
between O O
nucleus O O
and O O
synapse O O
that O O
may O O
provide O O
insight O O
into O O
normal O O
plasticity O O
and O O
the O O
etiology O O
of O O
intellectual O O
disability O O
. O O

[ O O
Cyclooxygenase B-group O
inhibitors I-group O
and O O
antiplatelet O O
effect O O
of O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
. O O
selective O O
approach O O
to O O
nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
in O O
cardiological O O
practice O O
] O O
. O O

Nonsteroidal B-group B-group
anti-inflammatory I-group I-group
drugs I-group I-group
( O O
NSAIDs B-group B-group
) O O
represent O O
class O O
of O O
medicines O O
which O O
is O O
wide O O
concerning O O
chemical O O
structure O O
and O O
mechanism O O
of O O
action O O
. O O

In O O
the O O
light O O
of O O
contradictory O O
data O O
on O O
efficacy O O
and O O
safety O O
of O O
NSAID B-group B-group
in O O
cardiovascular O O
patients O O
selection O O
of O O
most O O
appropriate O O
NSAID B-group B-group
( O O
basing O O
on O O
profile O O
of O O
efficacy O O
and O O
safety O O
) O O
in O O
patients O O
receiving O O
continuous O O
therapy O O
with O O
low O O
dose O O
aspirin B-brand B-brand
appears O O
to O O
be O O
a O O
problem O O
. O O

In O O
this O O
paper O O
we O O
discuss O O
peculiarities O O
of O O
drug O O
interaction O O
between O O
cyclooxygenase B-group B-group
inhibitors I-group I-group
and O O
acetylsalicylic B-drug B-drug
acid I-drug I-drug
, O O
and O O
principles O O
of O O
selection O O
of O O
adequate O O
NSAI B-group B-group
. O O

Tradition O O
and O O
toxicity O O
: O O
evidential O O
cultures O O
in O O
the O O
kava O O
safety O O
debate O O
. O O

This O O
paper O O
examines O O
the O O
debate O O
about O O
the O O
safety O O
of O O
kava O O
( O O
Piper O O
methysticum O O
Forst O O
. O O
f O O
, O O
Piperaceae O O
) O O
, O O
a O O
plant O O
native O O
to O O
Oceania O O
, O O
where O O
it O O
has O O
a O O
long O O
history O O
of O O
traditional O O
use O O
. O O

Kava O O
became O O
popular O O
as O O
an O O
anti-anxiety O O
treatment O O
in O O
Western O O
countries O O
in O O
the O O
late O O
1990s O O
, O O
but O O
it O O
was O O
subsequently O O
banned O O
in O O
many O O
places O O
due O O
to O O
adverse O O
reports O O
of O O
liver O O
toxicity O O
. O O

This O O
paper O O
focuses O O
on O O
the O O
responses O O
to O O
the O O
bans O O
by O O
scientists O O
involved O O
in O O
kava O O
research O O
, O O
contrasting O O
their O O
evidential O O
culture O O
with O O
that O O
employed O O
by O O
clinicians O O
and O O
regulatory O O
officials O O
. O O

Cultural O O
constructions O O
and O O
social O O
negotiations O O
of O O
risk O O
are O O
shown O O
to O O
be O O
context-specific O O
, O O
and O O
are O O
shaped O O
by O O
professional O O
, O O
disciplinary O O
, O O
and O O
organizational O O
factors O O
, O O
among O O
others O O
. O O

Though O O
the O O
science O O
of O O
hepatotoxicity O O
is O O
uncertain O O
enough O O
to O O
allow O O
for O O
multiple O O
interpretations O O
of O O
the O O
same O O
data O O
, O O
the O O
biomedical/clinical O O
narrative O O
about O O
kava O O
remains O O
dominant O O
. O O

This O O
case O O
study O O
explores O O
the O O
influence O O
of O O
these O O
cultural O O
, O O
social O O
, O O
and O O
political O O
factors O O
on O O
the O O
production O O
of O O
scientific O O
knowledge O O
and O O
the O O
assessment O O
of O O
benefit/risk O O
posed O O
by O O
comestibles O O
. O O

An O O
autopsy O O
case O O
of O O
multiple O O
psychotropic B-group B-group
drug I-group I-group
poisoning O O
. O O

A O O
fatal O O
poisoning O O
case O O
involving O O
etizolam B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
promethazine B-drug B-drug
and O O
chlorpromazine B-drug B-drug
is O O
presented O O
. O O

Quantitative O O
toxicological O O
analysis O O
showed O O
that O O
the O O
concentrations O O
of O O
etizolam B-drug B-drug
, O O
phenobarbital B-drug B-drug
, O O
promethazine B-drug B-drug
and O O
chlorpromazine B-drug B-drug
in O O
the O O
femoral O O
blood O O
were O O
86 O O
ng/ml O O
, O O
5082 O O
microg/ml O O
, O O
0.107 O O
microg/ml O O
and O O
0.144 O O
microg/ml O O
, O O
respectively O O
, O O
and O O
large O O
amounts O O
of O O
drugs O O
were O O
also O O
detected O O
in O O
the O O
stomach O O
contents O O
. O O

We O O
conclude O O
that O O
the O O
cause O O
of O O
death O O
was O O
due O O
to O O
the O O
interaction O O
of O O
multiple O O
psychotropic B-group B-group
drugs I-group I-group
. O O

It O O
makes O O
scents O O
. O O

Aromatherapy O O
, O O
and O O
the O O
claims O O
made O O
for O O
it O O
, O O
is O O
the O O
subject O O
of O O
the O O
second O O
article O O
in O O
our O O
six-part O O
series O O
on O O
alternative O O
and O O
complementary O O
therapies O O
. O O

Pulmonary O O
tuberculosis O O
: O O
clinical O O
features O O
and O O
patient O O
management O O
. O O

Pulmonary O O
tuberculosis O O
( O O
TB O O
) O O
is O O
a O O
common O O
infectious O O
disease O O
and O O
a O O
major O O
cause O O
of O O
illness O O
and O O
death O O
throughout O O
the O O
world O O
, O O
particularly O O
in O O
developing O O
countries O O
. O O

This O O
article O O
explores O O
the O O
difference O O
between O O
latent O O
TB O O
infection O O
and O O
active O O
TB O O
disease O O
, O O
and O O
discusses O O
the O O
pharmacological O O
management O O
of O O
TB O O
and O O
issues O O
around O O
adherence O O
to O O
medication O O
. O O

Although O O
TB O O
is O O
usually O O
managed O O
by O O
specialist O O
teams O O
it O O
is O O
essential O O
that O O
all O O
practitioners O O
have O O
an O O
understanding O O
of O O
the O O
signs O O
and O O
symptoms O O
of O O
the O O
disease O O
to O O
ensure O O
early O O
referral O O
and O O
accurate O O
diagnosis O O
. O O

In-vitro O O
antimicrobial O O
activity O O
and O O
synergistic/antagonistic O O
effect O O
of O O
interactions O O
between O O
antibiotics B-group B-group
and O O
some O O
spice O O
essential O O
oils O O
. O O

Spices O O
and O O
herbs O O
have O O
been O O
used O O
for O O
many O O
years O O
by O O
different O O
cultures O O
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
is O O
( O O
1 O O
) O O
to O O
investigate O O
in-vitro O O
antimicrobial O O
effects O O
of O O
different O O
spices O O
and O O
herbs O O
( O O
5 O O
species O O
: O O
Rosmarinus O O
officinalis O O
( O O
Rosemary O O
) O O
, O O
Coriandrum O O
sativum O O
( O O
coriander O O
) O O
, O O
Micromeria O O
fruticosa O O
( O O
L O O
. O O
) O O

Druce O O
subsp O O
. O O

Brachycalyx O O
P.H O O
. O O

Davis O O
( O O
White O O
micromeria O O
) O O
, O O
Cumium O B-brand
cyminum O O
( O O
cumin O O
) O O
, O O
Mentha O O
piperita O O
( O O
Peppermint O B-drug
) O O
against O O
different O O
bacteria O O
and O O
fungi O O
species O O
, O O
and O O
( O O
2 O O
) O O
to O O
discuss O O
the O O
in-vitro O O
possible O O
effects O O
between O O
the O O
plants O O
and O O
antibiotics B-group B-group
. O O

The O O
microorganisms O O
used O O
were O O
Micrococcus O O
luteus O O
LA O O
2971 O O
, O O
Bacillus O O
megaterium O O
NRS O O
, O O
Bacillus O O
brevis O O
FMC O O
3 O O
, O O
Enterococcus O O
faecalis O O
ATCC O O
15753 O O
, O O
Pseudomonas O O
pyocyaneus O O
DC O O
127 O O
, O O
Mycobacterium O O
smegmatis O O
CCM O O
2067 O O
, O O
Escherichia O O
coil O O
DM O O
, O O
Aeromonas O O
hydrophila O O
ATCC O O
7966 O O
, O O
Yersinia O O
enterocolitica O O
AU O O
19 O O
, O O
Staphylococcus O O
aureus O O
Cowan O O
1 O O
, O O
Streptococcus O O
faecalis O O
DC O O
74 O O
bacteria O O
, O O
and O O
Saccharomyces O O
cerevisiae O O
WET O O
136 O O
, O O
Kluvyeromyces O O
fragilis O O
DC O O
98 O O
fungi O O
in O O
this O O
study O O
. O O

The O O
results O O
indicated O O
that O O
essential O O
oils O O
of O O
Rosmarinus O O
officinalis O O
, O O
Coriandrum O O
sativum O O
L. O O
, O O
Micromeria O O
fruticosa O O
( O O
L O O
. O O
) O O

Druce O O
subsp O O
. O O

brachycalyx O O
P.H O O
. O O

Davis O O
, O O
Cumium O B-brand
cyminum O O
L. O O
, O O
Mentha O O
piperita O O
L O O
. O O

were O O
shown O O
antimicrobial O O
activity O O
in O O
the O O
range O O
of O O
7-60 O O
mm O O
2 O O
microl O O
( O O
-1 O O
) O O
inhibition O O
zone O O
to O O
the O O
microorganisms O O
tested O O
, O O
using O O
disc O O
diffusion O O
method O O
. O O

Standard O O
antibiotic B-group B-group
such O O
as O O
Gentamicin B-drug B-drug
( O O
10 O O
microg O O
) O O
, O O
Cephalothin B-drug B-drug
( O O
30 O O
microg O O
) O O
, O O
Ceftriaxone B-drug B-drug
( O O
10 O O
microg O O
) O O
, O O
Nystatin B-drug B-brand
( O O
10 O O
U O O
) O O
discs O O
were O O
used O O
for O O
comparison O O
with O O
the O O
antimicrobial O O
activities O O
of O O
essential O O
oils O O
of O O
these O O
plants O O
. O O

In O O
addition O O
, O O
antibacterial O O
activity O O
of O O
essential O O
oils O O
of O O
these O O
plants O O
was O O
researched O O
by O O
effects O O
when O O
it O O
was O O
used O O
together O O
with O O
these O O
standard O O
antibiotics B-group B-group
in O O
vitro O O
. O O

However O O
, O O
antibacterial O O
activity O O
changed O O
also O O
by O O
in O O
vitro O O
interactions O O
between O O
these O O
standard O O
antibiotics B-group B-group
and O O
essential O O
oils O O
of O O
these O O
plants O O
. O O

Synergic O B-brand
, O O
additive O O
or O O
antagonist O O
effects O O
were O O
observed O O
in O O
antibacterial O O
activity O O
. O O

Positive O O
shifts O O
of O O
the O O
GABAA O O
receptor O O
reversal O O
potential O O
due O O
to O O
altered O O
chloride O O
homeostasis O O
is O O
widespread O O
after O O
status O O
epilepticus O O
. O O

-Aminobutyric O O
acid O O
( O O
GABA O O
) O O
ergic O O
transmission O O
plays O O
an O O
important O O
role O O
in O O
the O O
initiation O O
of O O
epileptic O O
activity O O
and O O
the O O
generation O O
of O O
ictal O O
discharges O O
. O O

The O O
functional O O
alterations O O
in O O
the O O
epileptiform O O
hippocampus O O
critically O O
depend O O
on O O
GABAergic O O
mechanisms O O
and O O
cation-chloride O O
cotransporters O O
. O O

To O O
understand O O
the O O
cellular O O
basis O O
of O O
specific O O
functional O O
alterations O O
in O O
the O O
epileptic O O
hippocampus O O
, O O
we O O
studied O O
physiologic O O
characteristics O O
and O O
pharmacologically O O
isolated O O
evoked O O
GABA O O
( O O
A O O
) O O
receptor-mediated O O
inhibitory O O
postsynaptic O O
currents O O
( O O
IPSCs O O
) O O
recorded O O
from O O
principal O O
neurons O O
in O O
hippocampal O O
slices O O
from O O
status O O
epilepticus O O
( O O
SE O O
) O O
and O O
control O O
rats O O
using O O
whole-cell O O
and O O
gramicidin O O
perforated O O
patch-clamp O O
recordings O O
. O O

Whereas O O
the O O
resting O O
membrane O O
potential O O
and O O
input O O
resistance O O
were O O
not O O
significantly O O
different O O
between O O
control O O
and O O
epileptic O O
tissue O O
, O O
the O O
reversal O O
potential O O
( O O
E O O
( O O
GABA O O
) O O
) O O
of O O
IPSCs O O
was O O
significantly O O
shifted O O
to O O
more O O
positive O O
values O O
in O O
SE O O
rats O O
with O O
regard O O
to O O
the O O
resting O O
membrane O O
potential O O
. O O

Pharmacologic O O
experiments O O
and O O
quantitative O O
reverse O O
transcriptase O O
polymerase O O
chain O O
reaction O O
( O O
RT-PCR O O
) O O
showed O O
that O O
the O O
observed O O
changes O O
in O O
the O O
epileptic O O
tissue O O
were O O
due O O
to O O
a O O
decreased O O
ratio O O
of O O
the O O
main O O
Cl O B-drug_n
( O I-drug_n
- O I-drug_n
) O I-drug_n
extrusion O I-drug_n
transporter O I-drug_n
( O I-drug_n
K O I-drug_n
( O I-drug_n
+ O I-drug_n
) O I-drug_n
-Cl O I-drug_n
( O I-drug_n
- O I-drug_n
) O I-drug_n
cotransporter O I-drug_n
, O O
KCC2 O O
) O O
to O O
the O O
main O O
Cl O O
( O O
- O O
) O O
uptake O O
transporter O O
( O O
Na O O
( O O
+ O O
) O O
-K O O
( O O
+ O O
) O O
-2Cl O O
( O O
- O O
) O O
cotransporter O O
, O O
NKCC1 O O
) O O
. O O

Our O O
results O O
suggest O O
that O O
alterations O O
of O O
cation-chloride O O
cotransporter O O
functions O O
, O O
comprising O O
a O O
higher O O
NKCC1 O O
action O O
, O O
contribute O O
to O O
hyperexcitability O O
within O O
the O O
hippocampus O O
following O O
SE O O
. O O

Evaluation O O
of O O
hepatic O O
clearance O O
and O O
drug-drug O O
interactions O O
of O O
luteolin B-drug_n O
and O O
apigenin B-drug_n O
by O O
using O O
primary O O
cultured O O
rat O O
hepatocytes O O
. O O

The O O
hepatic O O
clearance O O
and O O
drug-drug O O
interactions O O
of O O
luteolin B-drug_n O
and O O
apigenin B-drug_n O
were O O
studied O O
by O O
using O O
primary O O
cultured O O
rat O O
hepatocytes O O
. O O

Luteolin B-drug_n B-drug
and O O
apigenin B-drug_n O
experienced O O
extensive O O
first-pass O O
metabolism O O
. O O

The O O
elimination O O
percent O O
of O O
luteolin B-drug_n O
and O O
apigenin B-drug_n O
was O O
found O O
to O O
be O O
91.9 O O
% O O
and O O
86.7 O O
% O O
after O O
120 O O
min O O
of O O
incubation O O
. O O

The O O
predicted O O
% O O
liver O O
blood O O
flow O O
was O O
82.3 O O
% O O
and O O
85.4 O O
% O O
for O O
luteolin B-drug_n O
and O O
apigenin B-drug_n O
, O O
respectively O O
. O O

Total O O
glucuronidated/sulfated O O
conjugates O O
of O O
luteolin/apigenin O O
were O O
determined O O
by O O
an O O
enzyme O O
hydrolysis O O
method O O
. O O

Compared O O
with O O
the O O
elimination O O
of O O
pure O O
luteolin B-drug_n O
and O O
apigenin B-drug_n O
, O O
the O O
elimination O O
of O O
luteolin B-drug_n O
and O O
apigenin B-drug_n O
was O O
much O O
lower O O
in O O
hydrolyzed O O
Flos O O
Chrysanthemi O O
extract O O
( O O
FCE O O
) O O
containing O O
comparable O O
amounts O O
of O O
luteolin B-drug_n O
and O O
apigenin B-drug_n O
. O O

The O O
effect O O
of O O
a O O
series O O
of O O
flavonoids B-drug_n O
, O O
including O O
flavonols B-drug_n B-drug
, O O
flavones B-drug_n B-group
, O O
isoflavone B-drug_n B-drug
, O O
flavanone B-drug_n B-drug
, O O
flavanonols B-drug_n B-drug
and O O
catechins B-drug_n O
, O O
on O O
the O O
elimination O O
of O O
luteolin B-drug_n O
and O O
apigenin B-drug_n O
was O O
studied O O
. O O

At O O
least O O
four O O
key O O
determinants O O
in O O
the O O
chemical O O
structures O O
of O O
flavonoids B-drug_n O
are O O
necessary O O
for O O
exerting O O
the O O
inhibitory O O
effects O O
on O O
the O O
conjugation O O
: O O
1 O O
) O O
catechol O O
structure O O
( O O
3',4'-dihydroxylation O O
) O O
in O O
the O O
B-ring O O
; O O

2 O O
) O O
B-ring O O
is O O
attached O O
to O O
the O O
C-2 O O
position O O
on O O
the O O
C-ring O O
; O O

3 O O
) O O
the O O
C2-3 O O
double O O
bond O O
in O O
conjunction O O
with O O
the O O
C4 O O
carbonyl O O
group O O
on O O
the O O
C-ring O O
; O O

4 O O
) O O
no O O
glycoside O O
present O O
. O O

Investigation O O
of O O
clearance O O
and O O
interaction O O
among O O
flavonoids B-drug_n O
could O O
help O O
us O O
better O O
understand O O
their O O
bioavailability O O
and O O
offer O O
insight O O
into O O
the O O
approaches O O
to O O
be O O
taken O O
to O O
minimize O O
competitive O O
effects O O
, O O
and O O
to O O
design O O
appropriate O O
bioavailability O O
studies O O
in O O
humans O O
. O O

Evaluation O O
of O O
antidepressant O B-group
like O O
activity O O
of O O
curcumin B-drug_n O
and O O
its O O
combination O O
with O O
fluoxetine B-drug B-drug
and O O
imipramine B-drug B-drug
: O O
an O O
acute O O
and O O
chronic O O
study O O
. O O

Curcumin B-drug_n B-drug_n
is O O
the O O
active O O
ingredient O O
of O O
commonly O O
used O O
spice O O
Curuma O O
longa O O
Linn O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
antidepressant O B-group
like O O
activity O O
of O O
curcumin B-drug_n O
and O O
its O O
combination O O
with O O
fluoxetine B-drug B-drug
and O O
imipramine B-drug B-drug
was O O
studied O O
in O O
acute O O
model O O
( O O
three O O
doses O O
24 O O
, O O
5 O O
and O O
1 O O
h O O
before O O
test O O
) O O
of O O
forced O O
swimming O O
test O O
( O O
FST O O
) O O
in O O
glass O O
jar O O
and O O
tail O O
suspension O O
test O O
( O O
TST O O
) O O
in O O
mice O O
and O O
in O O
chronic O O
model O O
( O O
14 O O
day O O
study O O
) O O
of O O
FST O O
with O O
water O O
wheel O O
in O O
rats O O
. O O

All O O
the O O
tests O O
were O O
carried O O
out O O
in O O
the O O
following O O
seven O O
groups O O
( O O
n O O
= O O
6 O O
in O O
each O O
group O O
) O O
, O O
drugs O O
being O O
given O O
orally O O
( O O
doses O O
for O O
mice O O
) O O
: O O
Group O O
1 O O
( O O
vehicle O O
) O O
, O O
group O O
2 O O
( O O
curcumin B-drug_n O
50 O O
mg/kg O O
) O O
, O O
group O O
3 O O
( O O
curcumin B-drug_n O
100 O O
mg/kg O O
) O O
, O O
group O O
4 O O
( O O
fluoxetine B-drug B-drug
20 O O
mg/kg O O
) O O
, O O
group O O
5 O O
( O O
imipramine B-drug B-drug
15 O O
mg/kg O O
) O O
, O O
group O O
6 O O
( O O
curcumin B-drug_n O
100 O O
mg/kg O O
plus O O
fluoxetine B-drug B-drug
20 O O
mg/kg O O
) O O
and O O
group O O
7 O O
( O O
curcumin B-drug_n O
100 O O
mg/kg O O
plus O O
imipramine B-drug B-drug
15 O O
mg/kg O O
) O O
. O O

Equivalent O O
doses O O
for O O
rats O O
were O O
used O O
. O O

Both O O
the O O
acute O O
model O O
of O O
FST O O
and O O
TST O O
, O O
and O O
the O O
chronic O O
model O O
of O O
FST O O
with O O
water O O
wheel O O
showed O O
significant O O
antidepressant O B-group
like O O
activity O O
of O O
curcumin B-drug_n B-drug_n
in O O
100 O O
mg/kg O O
dose O O
as O O
compared O O
to O O
vehicle O O
control O O
( O O
p O O
< O O
0.05 O O
) O O
. O O

The O O
effect O O
of O O
curcumin B-drug_n B-drug_n
( O O
100 O O
mg/kg O O
) O O
was O O
similar O O
to O O
that O O
of O O
fluoxetine B-drug B-drug
and O O
imipramine B-drug B-drug
( O O
p O O
> O O
0.05 O O
) O O
but O O
its O O
addition O O
to O O
fluoxetine B-drug B-drug
and O O
imipramine B-drug B-drug
did O O
not O O
improve O O
their O O
antidepressant O O
activity O O
( O O
p O O
> O O
0.05 O O
) O O
. O O

Curcumin B-drug_n B-drug_n
increased O O
both O O
the O O
swimming O O
and O O
climbing O O
behavior O O
in O O
FST O O
, O O
thus O O
its O O
antidepressant O B-group
like O O
activity O O
could O O
be O O
due O O
to O O
an O O
increase O O
in O O
serotonin O O
, O O
norepinephrine O B-drug
and O O
dopamine O O
levels O O
in O O
the O O
brain O O
. O O

Curcumin B-drug_n B-brand
can O O
be O O
a O O
useful O O
antidepressant B-group B-group
especially O O
in O O
cases O O
which O O
respond O O
to O O
drugs O O
having O O
mixed O O
effects O O
on O O
serotonin O O
and O O
catecholamines O O
levels O O
in O O
the O O
brain O O
. O O

[ O O
Polypharmacy O O
and O O
drug O O
interactions O O
] O O
. O O

The O O
growing O O
consumption O O
of O O
drugs O O
and O O
other O O
numerous O O
factors O O
relates O O
to O O
the O O
increasing O O
incidence O O
of O O
polypharmacy O O
. O O

The O O
proportion O O
of O O
patients O O
currently O O
treated O O
with O O
5 O O
or O O
more O O
medicines O O
at O O
the O O
elderly O O
population O O
in O O
particular O O
is O O
30-60 O O
% O O
of O O
patients O O
. O O

Repeatedly O O
has O O
been O O
proven O O
the O O
dependence O O
between O O
the O O
number O O
of O O
concomitant O O
drugs O O
and O O
occurrence O O
of O O
adverse O O
effects O O
, O O
patients O O
requiring O O
hospitalization O O
, O O
or O O
incidence O O
of O O
moderate O O
and O O
serious O O
drug O O
interactions O O
. O O

Some O O
works O O
show O O
that O O
it O O
is O O
possible O O
to O O
satisfactorily O O
address O O
the O O
issues O O
of O O
polypharmacy O O
, O O
but O O
it O O
requires O O
great O O
courage O O
and O O
an O O
interdisciplinary O O
approach O O
involving O O
modern O O
information O O
technology O O
. O O

[ O O
Vitamin B-group B-group
D I-group I-group
and O O
drugs O O
] O O
. O O
; O O

Interactions O O
between O O
drugs O O
and O O
vitamin B-group B-group
D I-group I-group
have O O
received O O
only O O
little O O
or O O
no O O
attention O O
in O O
the O O
medical O O
and O O
pharmaceutical O O
world O O
in O O
the O O
past O O
. O O

Since O O
more O O
and O O
more O O
drugs O O
are O O
used O O
for O O
the O O
treatment O O
of O O
patients O O
, O O
this O O
topic O O
is O O
increasingly O O
relevant O O
. O O

As O O
such O O
interactions O O
impact O O
the O O
health O O
of O O
the O O
patient O O
and O O
the O O
action O O
and O O
side O O
effects O O
of O O
the O O
drug O O
, O O
physicians O O
and O O
pharmacists O O
should O O
pay O O
more O O
attention O O
to O O
such O O
interactions O O
in O O
the O O
future O O
. O O

A O O
number O O
of O O
drugs O O
can O O
interfere O O
with O O
the O O
vitamin B-group B-group
D I-group I-group
and O O
bone O O
metabolism O O
. O O

The O O
drug-induced O O
activation O O
of O O
the O O
pregnane O O
X O O
receptor O O
( O O
PXR O O
) O O
is O O
likely O O
to O O
enhance O O
CYP24 O O
expression O O
and O O
the O O
catabolism O O
of O O
25 O O
( O B-drug_n
OH O I-drug_n
) O I-drug_n
D O I-drug_n
, O O
leading O O
to O O
vitamin O B-group
D O I-group
deficiency O O
. O O

PXR-ligands O O
include O O
a O O
wide O O
variety O O
of O O
pharmaceutical O O
agents O O
, O O
such O O
as O O
antiepileptic B-group B-group
drugs I-group I-group
, O O
taxol B-brand B-brand
, O O
rifampicin B-drug B-drug
, O O
and O O
human B-group B-group
immunodeficiency I-group I-group
virus I-group I-group
protease I-group I-group
inhibitors I-group I-group
such O O
as O O
ritonavir B-drug B-drug
and O O
saquinavir B-drug B-drug
. O O

Beside O O
this O O
, O O
the O O
medication O O
oriented O O
supplementation O O
of O O
vitamin B-group B-group
D I-group I-group
can O O
also O O
ameliorate O O
the O O
pharmacologic O O
action O O
of O O
many O O
drugs O O
, O O
such O O
as O O
bisphosphonates B-group B-group
, O O
statins B-group B-group
and O O
cytostatic B-group O
drugs I-group O
. O O

[ O O
Drug O O
interactions O O
on O O
P-glycoprotein O O
transport O O
level O O
and O O
its O O
application O O
] O O
. O O

Potential O O
drug O O
interactions O O
on O O
P-glycoprotein O O
transport O O
level O O
were O O
discussed O O
in O O
this O O
article O O
. O O

As O O
an O O
efflux O O
transporter O O
protein O O
widely O O
distributed O O
in O O
various O O
tissues O O
, O O
P-glycoprotein O O
plays O O
an O O
important O O
role O O
in O O
many O O
drugs O O
interactions O O
, O O
via O O
affecting O O
the O O
metabolic O O
process O O
to O O
alter O O
the O O
concentration O O
of O O
drug O O
in O O
plasma O O
and O O
tissue O O
. O O

Interactions O O
between O O
herb O O
and O O
western O O
drug O O
may O O
occur O O
by O O
inducing O O
or O O
inhibiting O O
P-glycoprotein O O
, O O
resulting O O
in O O
either O O
efficacy O O
enhancement O O
or O O
adverse O O
effects O O
. O O

So O O
it O O
is O O
important O O
for O O
clinical O O
drug O O
use O O
by O O
rational O O
utilization O O
of O O
the O O
interaction O O
between O O
herb O O
and O O
western O O
drug O O
which O O
medicated O O
by O O
P-glycoprotein O O
. O O

[ O O
Summary O O
of O O
revised O O
contents O O
of O O
medical O O
standards O O
of O O
preparation O O
recorded O O
in O O
Chinese O O
Pharmacopeia O O
( O O
I O O
division O O
, O O
2010 O O
edition O O
) O O
] O O
. O O

China O O
pharmacopoeia O O
is O O
a O O
civil O O
code O O
which O O
is O O
to O O
ensure O O
pharmaceutical O O
quality O O
and O O
protect O O
people O O
's O O
drug O O
safety O O
and O O
effectiveness O O
. O O

Drug O O
standards O O
are O O
consist O O
of O O
two O O
parts O O
, O O
the O O
pharmaceutical O O
standards O O
and O O
medical O O
standards O O
. O O

Medical O O
standards O O
include O O
four O O
contents O O
, O O
such O O
as O O
prescription O O
, O O
function O O
and O O
indications O O
, O O
usage O O
and O O
dosage O O
and O O
attentions O O
. O O

This O O
paper O O
summarized O O
the O O
revised O O
contents O O
of O O
medical O O
standards O O
and O O
suggested O O
some O O
propositions O O
. O O

Determination O O
of O O
propiverine B-drug B-drug
hydrochloride I-drug I-drug
in O O
human O O
plasma O O
by O O
high O O
performance O O
liquid O O
chromatography-tandem O O
mass O O
spectrometry O O
: O O
application O O
to O O
the O O
pharmacokinetic O O
study O O
of O O
a O O
sustained O O
release O O
formulation O O
. O O

A O O
rapid O O
, O O
sensitive O O
and O O
reliable O O
high O O
performance O O
liquid O O
chromatography-tandem O O
mass O O
spectrometry O O
( O O
HPLC-MS/MS O O
) O O
method O O
was O O
developed O O
and O O
validated O O
for O O
the O O
determination O O
of O O
propiverine B-drug B-drug
hydrochloride I-drug I-drug
( O O
CAS O O
54556-98-8 O O
) O O
in O O
human O O
plasma O O
using O O
cetirizine B-drug B-drug
di-hydrochloride I-drug I-drug
as O O
internal O O
standard O O
( O O
IS O O
, O O
CAS O O
8388-51-0 O O
) O O
. O O

Following O O
liquid-liquid O O
extraction O O
with O O
ethyl B-drug_n B-drug
acetate I-drug_n I-drug
, O O
the O O
separation O O
was O O
performed O O
on O O
a O O
reverse O O
phase O O
C18 O O
column O O
with O O
a O O
mobile O O
phase O O
consisted O O
of O O
methanol-ammonium B-drug_n B-drug
acetate I-drug_n I-drug
( O O
pH O O
4.0 O O
; O O
10 O O
mM O O
) O O
( O O
70:30 O O
, O O
v/v O O
) O O
. O O

The O O
detection O O
was O O
performed O O
by O O
a O O
triple-quadrupole O B-drug
mass O O
spectrometer O O
in O O
the O O
positive O O
ion O O
and O O
multiple O O
reaction O O
monitoring O O
( O O
MRM O O
) O O
mode O O
, O O
m/z O O
368.3 O O
-- O O
> O O

116.1 O O
for O O
propiverine B-drug B-drug
and O O
m/z O O
389.2 O O
-- O O
> O O

201.0 O O
for O O
the O O
IS O O
. O O

The O O
calibration O O
curve O O
fitted O O
well O O
over O O
the O O
concentration O O
range O O
of O O
0.2-200 O O
ng/mL O O
( O O
all O O
the O O
concentration O O
data O O
in O O
this O O
study O O
are O O
related O O
to O O
salt O O
( O O
propiverine B-drug B-drug
hydrochloride I-drug I-drug
) O O
) O O
. O O

The O O
limit O O
of O O
detection O O
( O O
LOD O O
) O O
and O O
lower O O
limit O O
of O O
quantification O O
( O O
LLOQ O B-drug_n
) O O
in O O
human O O
plasma O O
were O O
0.05 O O
and O O
0.2 O O
ng/mL O O
, O O
respectively O O
. O O

The O O
method O O
was O O
proved O O
to O O
be O O
rapid O O
, O O
sensitive O O
, O O
specific O O
, O O
accurate O O
and O O
reproducible O O
and O O
has O O
been O O
successfully O O
applied O O
to O O
a O O
pharmacokinetic O O
study O O
of O O
propiverine B-drug B-drug
hydrochloride I-drug I-drug
sustained O O
release O O
capsules O O
( O O
the O O
30 O O
mg O O
dose O O
in O O
this O O

